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Abstract: 
Background  
  An association between migraine and obesity has been identified. Currently no 
causality has been identified. Certain appetite behaviours put individuals at 
increased risk of obesity. Appetite behaviours have not been thoroughly examined 
in the paediatric migraine population. Work has shown that migraineurs crave 
carbohydrates around time of attack, that anorexia can exacerbate a migraine and 
that migraineurs often avoid certain foods that supposedly trigger their migraine. 
Hitherto no formal study of trait appetite behaviours in migraineurs has been 
conducted. Theoretically, aberrant appetite behaviours in migraineurs may mediate 
the onset of obesity.  
Aims           
            
The aims of this study were multiple. Firstly, it was to undertake a formal 
literature review into the area of the relationship between migraine and obesity. 
Secondly it was to design a study assessing the relationship between migraine and 
appetite behaviour. Thirdly it was to examine, within the study, the feasibility and 
utility of the recruitment process and the psychometric tools respectively.  
   Methods 
The study was a pilot, cross-sectional questionnaire based study. Migraine patients 
were recruited from the tertiary paediatric clinics at Alder Hey Children‘s 
Foundation Trust Hospital. Inclusion criteria were a diagnosis of migraine based on 
clinical criteria by the treating paediatrician; participants were aged between 5 and 
16 years, including both sexes; participants were new referrals to Alder Hey 
neurology department and were migraine medication drug naïve. Exclusion criteria 
were that children were under 5 years old or over 16 years of age; or had a known 
presence of secondary cause of migraine-like headache e.g. brain tumour. Specific 
psychometric tools were utilised as the primary and secondary outcome measures 
for predicting migraine severity, appetite behaviour, food cravings, food intake and 
behavioural psychology. All of these psychometric tools were answered at a one off 
interview with the participants. 
    Results 
A comprehensive literature search and thorough study design were achieved, with 
the study gaining ethical and site-specific approval. The limited sample size gained 
from the early recruitment phase prevents insights into the relationship between 
migraine and appetite behaviour. A great deal about recruitment utility and 
suitability of psychometric tools was gleaned from early stages of recruitment.  
  Conclusion 
Drawing robust conclusions about the relationship between appetite behaviour and 
migraine from this study is not possible. There are, however, some interesting 
preliminary results about the study design and tools of the study. 
Recommendations were designed to improve the study design in response to the 
qualitative findings, in order that robust quantitative findings can be elucidated 
when the study is continued to completion.  
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Chapter 1: Introduction: 
 
Chapter 1: 1 what is migraine? 
1.1.1 Definition and prevalence of migraine 
Childhood headaches are a very common paediatric problem. Primary 
headaches are those in which there are episodic headaches in the absence of a 
structural cause.  Paediatric migraine is the most prevalent primary 
headache(1). Migraine has a childhood prevalence of 9.7-10.8% in school age 
children(2-4). Interestingly, migraine prevalence increases with childhood 
age, being rare before the age of two and as high as 20% in elder 
adolescence(5). The average age of onset is 6 years old(7), with the 
prevalence higher in boys until puberty, when the pattern reverses (6). The 
majority of adults have their first headache diagnosed in childhood or 
adolescence(5, 6), hence it is clear to see the burden this disease has on the 
paediatric population. That being said, paediatric headache disorders are 
considered to be an understudied area(7), with much still to be discovered 
and understood about the pathogenesis of headaches and, in particular, 
migraine. Moreover, much is to be revealed about genetic, environmental 
and crucially neurobiological mechanisms regarding migraine(8). 
 
The international headache society(IHS)(9) for diagnosing migraine (see 
classification below) highlights that it is based upon positive clinical findings; 
typically of unilateral headache with features such as nausea, vomiting, 
photophobia, amongst others. In contrast, another primary headache, namely 
tension type headache, is classically bilateral, often more mild and without 
associated features. In the last decade it has been increasingly agreed that 
each of these headaches share a lot of similar features, and it is now in 
contention as to whether it is valid, or indeed practical, to classify them as 
separate entities, or whether they are part of one headache type(10). 
Furthermore, headaches can present as chronic daily headaches, whereby 
headache occurs 15 days a month or more(11). This form of headache is 
particularly troublesome to diagnose and classify.  Headache is one of the 
commonest referrals from general practitioners to paediatric neurology 
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making up 27% of referrals (based on an unpublished audit conducted at 
Alder Hey this year). Clinic populations are patients at the more severe end 
of the severity spectrum and generally those patients most likely to suffer 
from co-morbidity. 
 
1.1.2 Diagnosis and classification of Migraine(12) 
The two most common forms of migraine are migraine with aura and 
migraine without aura. The classification of these is below. The classification 
of chronic migraine and a more through classification of migraine with and 
without aura are in the appendix (Appendix A).  
 Migraine without aura 
Description: 
Recurrent headache disorder manifesting in attacks lasting 4-72 hours. 
Typical characteristics of the headache are unilateral location, pulsating 
quality, moderate or severe intensity, aggravation by routine physical 
activity and association with nausea and/or photophobia and phonophobia. 
Diagnostic criteria: 
A. At least 5 attacks fulfilling criteria B-D 
B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully 
 treated) 
C. Headache has at least two of the following characteristics: 
1. Unilateral location 
2. Pulsating quality 
3. Moderate or severe pain intensity 
4. Aggravation by or causing avoidance of routine physical activity (e.g. 
 walking or climbing stairs) 
D. During headache at least one of the following: 
1. Nausea and/or vomiting 
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2. Photophobia and phonophobia 
E. Not attributed to another disorder 
Migraine with aura(12) 
Description: 
Recurrent disorder manifesting in attacks of reversible focal neurological 
symptoms that usually develop gradually over 5-20 minutes and last for less 
than 60 minutes. Headache with the features of migraine without aura 
usually follows the aura symptoms. Less commonly, headache lacks 
migrainous features or is completely absent. 
Diagnostic criteria: 
A. At least 2 attacks fulfilling criteria B–D 
B. Aura consisting of at least one of the following, but no motor 
 weakness: 
 1.  Fully reversible visual symptoms including positive features (e.g. 
flickering lights, spots or lines) and/or negative features (i.e. loss of vision) 
 2.     Fully reversible sensory symptoms including positive features (i.e., pins 
and needles) and/or negative features (i.e., numbness) 
 3.     Fully reversible dysphasic speech disturbance 
 
C.    At least two of the following: 
1.    Homonymous visual symptoms and/or unilateral sensory symptoms 
2.    At least one aura symptom develops gradually over 5 minutes and          
 different aura symptoms occur in succession over 5 minutes 
3.    Each symptom lasts 5 and 60 minutes 
D. Headache fulfilling criteria B-D for Migraine without aura (above) 
 begins during the aura or follows aura within 60 minutes 
E. Not attributed to another disorder 
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1.1.3 Pathophysiology of migraine 
 
The pathophysiology of migraine is complex, and still not completely 
answered. Migraine is a primary brain disorder, which can cause significant 
burden. It has been shown to have a strong genetic link(13, 14). 
 
1.1.4 Hyperexcitability 
 
One theory of migraine pathophysiology is that the neurons in the cerebral 
cortex are hyperexcitable in migraine sufferers(15). Studies have shown, 
though not unanimously, that there is thus a persistent excitability lending 
to a susceptibility to migraine in the sufferer(16-18). In a certain type of 
migraine, namely familial hemiplegic migraine, it has been shown that a 
calcium channelopathy, caused by a gene defect (the CACNA1A gene(19)) is 
the cause of the hyperexcitability in neurons. To what extent this is the case 
in all migraine remains unclear. In migraine sufferers there is a lowered 
threshold to internal and external stimuli. Certain stimuli can trigger a wave 
of deregulated cortical function, which can lead to large swings of increased 
or decreased excitability(20). This is thought to lead to cortical spreading 
depression (CSD).  
 
1.1.5 Cortical Spreading Depression 
 
CSD is instrumental in migraine pathogenesis. Incidentally discovered over 
60 years ago(21), one theory suggests that cortical spreading depression 
leads to the triggering of a migraine aura and the activation of the 
trigeminovascular system(22). CSD is a self-propagating, depolarization of 
neurons and glia. Unequivocal evidence to its exact role is still not clear. 
Some studies suggest it triggers the trigeminovascular system (see 
below)(23, 24).  What has been shown is that there is ―depressed neuronal 
electrical activity with transient loss of membrane ionic gradients, with 
massive surges of extracellular potassium, intracellular calcium as well as 
neurotransmitters(25)‖. CSD spread is indiscriminate, and its spread 
infringes on pial arteries and venous circulation. This leads to a brief 
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hyperemia, but is subsequently followed by a prolonged oligaemia(22, 26-29). 
Twenty percent (20%) of migraine sufferers have an aura prior to the onset 
of a migraine, and it has been proposed that CSD is the cause of the aura(22). 
A caveat to this is a recent review of a number of cases of patients who had 
treatment that removed their aura whilst their headache remained, 
questioning whether CSD is a necessary prerequisite to migraine(30). 
 
1.1.6 The root of pain - peripheral versus central sensitization 
 
The link between CSD and the pain aspect of migraine is still unclear(25).  It 
remains contentious as to whether CSD can cause pain(25); or whether it is 
CSD triggering the trigeminovascular system or triggering the brain stem 
itself that leads to pain(24) . Until end of the 20th century, it was generally 
accepted that migraine was a vasogenic pathology. 
 
According to this theory, the pain caused by headache was thought to be due 
to neurogenic inflammation and dilatation of large cranial vessels and dura 
mater, mediated principally by CGRP, substance P and neurokinin A(31). It 
was proposed that this neurogenic inflammation lead to stimulation of 
nociceptive pathways in the trigeminal meningeal afferents that cause severe 
pain. In essence, the theory was that pain originates in peripheral nociceptors 
of meninges and meningeal blood vessels (coined ‗peripheral sensitization‘) 
due to this sterile inflammation, hypoperfusion and subsequent 
vasodilatation(31).  
 
There are a number of components to migraine attacks that are not fully 
explained by the peripheral sensitization/vasogenic theory. Firstly, the 
vasogenic theory doesn‘t account for the ‗prodromal‘ symptoms that occur in 
certain suffers. Classic prodromal symptoms, such as fatigue or inattention, 
precede any vascular changes by up to 24 hours(32). Secondly, aura 
symptomatology can have a wide spectrum within one attack in an individual 
(with a combination of speech, language and visual disturbances), 
transcending the known neurovascular boundaries, suggesting that aura isn‘t 
completely explained by the vasogenic theory(33). The increasing use of 
functional imaging has helped improve knowledge of migraine 
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pathophysiology over the last fifteen years. Positron Emission Tomography 
(PET) scans of migraine patients whilst in attack, have shown that blood 
flow patterns don‘t follow normal neurovascular patterns(34). Furthermore, 
Magnetic Resonance Imaging (MRI) studies of patients within migraine 
attack highlighted that reductions in blood flow were not significant enough 
to cause a degree of ischaemia necessary to explain the migraine 
symptomatology being experienced by subjects(35). 
 
Further innovative neuro-imaging research has identified a potential 
alternative migraine pathophysiology. Blood Oxygen Level Dependent 
(BOLD) Functional MRI (fMRI) studies implicated the midbrain in the 
generation of migraine attack and pain processing(36). Signal intensity 
increases were shown in the red nucleus, substantia nigra and periaquaductal 
grey matter consistently whilst patients where enduring their migraine 
attack. Further PET scan studies supported this work; in patients with 
spontaneous migraine attacks (both with and without aura) there were 
significant increases in signal intensity of the dorsal pons, amongst other 
areas of the brain stem(37).  
 
These recent neuro-imaging studies suggest that a migraine generator 
probably exists in the midbrain. This moves away from the concept of a 
vascular process underpinning migraine pathophysiology and towards the 
possibility of a neurogenic process being the key to migraine attacks; this 
theory is being coined ‗central sensitization‘.  
 
CSD is still implicated in this updated migraine pathogenesis; this has been 
reiterated by further neuro-imaging studies. It is thought that CSD is still 
the first step in migraine pathogenesis, leading to brainstem activation(35, 
38). It is thought that dysregulation of the brain stem underpins the sensory 
(particularly nociceptive) modulation of neurovascular afferents.  
 
What remains to be illuminated in migraine pathogenesis is what triggers 
the pain mechanism? For the majority of the twentieth century it was 
accepted that vasoconstriction triggered the pain process, whilst modern 
neuro-imaging implicates the brain stem heavily in migraine pathogenesis. 
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Subsequently it has been suggested there may be a brainstem generator that 
triggers the pain process.  
 
It must be noted that the most recent migraine therapy to be trialled 
successfully, the Calcitonin Gene-Related Peptide Receptor Antagonists, or 
‗gepants‘, which successfully abort migraine attacks, have no role in altering 
the vasculature in a migraine attack, thereby further supporting the central 
sensitization theory as the originator of migraine pain. Although many feel 
this model has superseded the vascular model, it remains contentious(39).  It 
is clear to see that a comprehensive unified theory of migraine pathogens 
currently remains elusive.  
 
1.1.7 The impact of migraine  
 
The spectrum of migraine severity, and hence its impact on a sufferer‘s 
quality of life, is very wide. Previous work suggests that migraine can 
significantly reduce the quality of life for migraine suffers in both school and 
social functioning(40). Recent work suggests that the majority of paediatric 
migraine sufferers can be categorised to have a mild disability. Of those 
migraineurs that present to tertiary clinics, however, a greater proportion 
have a higher disability level(41); to the degree that migraine limits their 
curricular and extracurricular ability at least third of the time(42). One study 
suggests migraine attacks cause school absence in 36.1% of migraineurs(43). 
No work has hitherto focused on relationships between severity of migraine 
and amount of school absence.  
 
 1.1.8 Migraine transformation 
 
A crucial part of the pathophysiology of migraine is the recent concept that a 
proportion of migraine sufferers do not have a static disease, but rather a 
sub-group have migraine transformation. This term means the progression 
of migraine from low frequency episodic headache leading to high frequency 
episodic headache and finally to chronic daily headaches. This transformation 
may cause progression to stroke or the occurrence of brain lesions (due to 
frank lack of blood flow resulting from spasm of blood vessels(15-17)).  It 
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has, therefore, been accepted that it is crucial that risk factors for this form of 
headache are highlighted to control or prevent them and hence ameliorate 
the devastating effects migraine can have if left to progress. Recently it has 
been shown in adults that a key risk factor for migraine progression is 
obesity(44). Crucially, this is a potentially modifiable risk factor, unlike age. 
 
1.1.9 Treatment of migraine  
 
Non-pharmacological: 
General measures: 
Self help strategies have been anecdotally reported to reduce the burden of 
migraine. These include avoiding stress, good ‗sleep hygiene‘ - regular 
bedtimes and not watching television directly before bed amongst others. 
Maintaining good hydration, eating regularly and avoiding known 
precipitants are beneficial(45). 
 
Behavioural interventions: 
Thermal biofeedback, which involves attempting to alter skin temperature by 
responding to feedback about this temperature, can be used as an 
intervention. Alternatively, progressive muscle relaxation, or hypnosis and 
self-administered stress management have been reported to reduce 
headaches(45). Currently, no direct comparisons of these behavioural 
techniques versus pharmacological therapy have been conducted. There is 
little evidence of how successful these treatments are in large migraine 
populations(46).  
 
Pharmacological treatments: 
It should be noted that not all of the treatments (acute relief or prophylactic) 
for migraine are licensed for use on children(45). Below is a review of the 
options available for migraine treatment. Those that are unlicensed are 
noted. The effectiveness of these medications in children is not fully known, 
simply because randomised control trials (RCT) have not be conducted(45). 
Two of the most commonly prescribed prophylactic medications, namely 
Pizotifen and Propranolol, are only currently being compared in an RCT(47).  
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Treatment of acute attacks: 
Simple analgesia: 
Paracetamol is often first line therapy(45); it has previously been shown to be 
twice as likely as placebo to alleviate pain. It can cause hepatic impairment in 
overdose. Rarely it can also cause rashes and blood disorders. Ibuprofen, a 
non-steriodal anti inflammatory drug (NSAID), has been shown to have 
similar efficacy in treating migraine pain as Paracetamol(45). Ibuprofen can 
cause gastrointestinal upset and even stomach ulceration; other side effects 
include an hypersensitivity reaction and drowsiness(48).  Aspirin is not to be 
used in children under 16 due to the association with Reye‘s syndrome(45). 
 
Tryptamines (Triptans): 
The ‗triptans‘ are serotonin agonists. They are administered in a migraine 
attack. They are reserved for patients unresponsive to conventional 
analgesics(49).  Sumatriptan, a nasal spray, is licensed in the United 
Kingdom (UK) for 12-17 year olds for acute relief/treatment of migraine 
with or without aura. Nausea, vomiting and tingling/heaviness of neck and 
chest are reported side effects(49).  Alternative triptans include Zolmitriptan, 
Rizatriptan, and Almotriptan. There are currently no studies in the 
paediatric population comparing the triptans(45). 
 
 Antiemetics: 
Ideally administered early after the onset of a migraine attack, antiemetics 
may reduce nausea and vomiting in older children in whom these symptoms 
occur regularly. Options of antiemetic include Metoclopramide and 
Domperidone(50). Metoclopramide has rare but serious extrapyramidal side 
effects. Other more common side effects are drowsiness, anxiety and 
restlessness(51). Domperidone has rare side effects of gastro-intestinal 
upset(52). 
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Prophylactic treatment of migraine: 
 Pizotifen:  
 Pizotifen is an histamine (H1) and serotonin receptor antagonist, it is 
licensed for the prevention of migraine in children over 2 years old. It is 
considered to be the first line preventative therapy for migraine, however, it 
has a number of unwanted side effects. Of particular relation to this study, 
increased appetite and subsequent weight gain are common side effects(45, 
50, 53). Drowsiness is another common side effect.  
 
Propranolol: 
Propranolol is commonly used for migraine in children, but is 
contraindicated in asthmatics(45). Side effects include reduced energy, 
tiredness and depressive symptoms. Its effectiveness in the treatment of 
paediatric migraine is not established, in spite of its regular use in the 
management of migraine(54).  
 
Amitriptyline: 
Although there are no randomized control trials of the use of Amitriptyline 
in the management paediatric migraine, it is sometimes used as a 
prophylactic migraine medication(45). It can reduce the severity and length 
of a migraine attack.  Sedation is a common side effect of Amitriptyline.  
 
Anti-epileptic drugs: 
Increasing evidence is emerging that antiepileptic drugs help reduce 
migraine morbidity(45). 
 
Topiramate: 
In particular, Topiramate is shown be effective in reducing mean migraine 
frequency(55). A common side effect of Topiramate is weight loss. One study 
showed that 37% of patients had a mean weight loss of 5.1kg over a period of 
four months on the drug(56). Another side effect is sensory changes.  
 
Levetiracetam:  
No randomized trials have been published about Levetiracetam in paediatric 
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migraine prophylaxis. It is currently not licensed as a migraine prophylactic 
medication in children. An open label prospective trial on twenty patients, 
however, showed 90% of patients had reduced headache frequency and 
morbidity(22). Common side effects include nausea, vomiting, diarrhoea and 
dyspepsia(57). 
 
It is clear that the management of migraine is varied. General measures are 
important such as good sleep hygiene. Consideration of general behavioural 
interventions, such as muscle relaxation is important. Simple analgesia 
should be the first pharmacological step, followed, if necessary, by acute relief 
medication. Prophylactic medication should be reserved for frequent or 
severe migraine. It is relevant to this author‘s research that two of the 
prophylactic medications, namely Pizotifen and Topiramate, have an effect 
on appetite and weight. Hitherto no study has fully uncovered the 
mechanisms behind this. 
 
1.1.10 Migraine and associated co-morbidities 
 
Migraine has a number of co-morbidities. These include sleep problems, 
stress, obesity, appetite problems and depression, amongst others(58). This 
study aims to focus on one of these co-morbidities, obesity, or more 
specifically, appetite behaviours that theoretically can lead to obesity. There 
is much neurobiological overlap between migraine, appetite and obesity that 
will be explored in chapter 1.4. Furthermore, there is phenomenology that 
anticipatory stimuli can trigger migraine attacks. This ties in with the 
hedonic concept of want for foods that will be covered in chapter 1.3. A 
review of the potential relationship between migraine, appetite and obesity is 
now necessary.  
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Chapter 1:2 – What is obesity? 
 
1.2.1 Definition and measurement of obesity 
 
Obesity has been defined as ―a condition of excess body fat that may harm 
health(59)‖. In the adult population, overweight is defined as a body mass 
index (BMI) greater than 25 and obese is defined as a BMI greater than 30 
(60). There is no unanimously accepted definition of overweight and obese 
thresholds in children and adolescents(61), because definition is difficult in 
this age group(62, 63). Various criteria have been designed to assess 
overweight and obese status in this age group. These include earlier methods 
such as measuring triceps skin folds(64), to more intensive methods such as 
Magnetic Resonance Imaging(MRI)(65). Ultimately, the optimal 
measurement of paediatric obesity would reflect levels of increased adiposity 
and associated risk of morbidity(61). An important distinction in 
measurement of increased adiposity is whether adiposity is measured 
directly, for example by dual energy X-ray absorptiometry (DXA), or 
indirectly by weight based measurements such as BMI. Pragmatically, 
weight definitions, based on simple anthropometric measurements (that have 
reasonable accuracy) are useful. They can be utilized in a range of settings 
such as population surveillance and for population studies. In children, 
however, simple BMI is not an accurate measurement of adiposity across a 
spread of ages(61). Ratios of lean to fat mass vary in children as they 
grow(66), particularly around the maturation stage (67). 
 
Thus, it is clear to see, obesity cannot be simply seen as an increase in 
weight, but rather as an increase in fat mass(68). Arguably, this is no 
startling revelation, but much early work on childhood obesity did not even 
accurately define obesity(69). The fact that there are no international agreed 
thresholds of overweight and obese in this age group, is testament to the 
arduousness of defining and accurately measuring childhood obesity. 
Currently, in the United States, the 85th and 95th percentile of body mass 
index (BMI), which are sex and age specific, are set as cut offs for overweight 
and obese(70, 71). These are based on national survey data, but are still 
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criticised as being rather arbitrarily defined cut offs(70). In the U.K, at the 
turn of the millennium, under an initiative from the International Obesity 
Task Force(72), there was a focus to formally design a more accurate 
measure of children‘s body fat. As such, BMI-z scores have been 
calculated(70). Essentially, the cut-off scores of adult BMI are linked to 
children‘s BMI percentiles. The reference population utilised was from a 
heterogeneous mix of survey data from several different countries, which had 
large variations in overweight and obesity prevalence(70). Thus, from these 
growth centile curves, one can calculate whether a child is overweight or 
obese, by referring to their age and sex specific international cut-off points 
for BMI z-scores.  The cut-off points, therefore, pass through the BMI of 25 
(upper scale of normal weight) and 30 (obese) at age 18(70). In the U.K, 
BMI-z scores are currently considered the best indirect measurement of 
adiposity on a single occasion(73). It may not, however, be the optimal 
measurement for tracking a child‘s fat mass over time(73). Notably, other 
less commonly used methods of measuring a children‘s fat mass include waist 
circumference, relative BMI, skin fold thickness, bioelectrical impedance and 
air displacement plethysmography, with the latter mostly utilized in 
research(59, 71, 74, 75). 
 
1.2.2 Prevalence of Obesity 
 
The prevalence of overweight or obese children aged 2-15 in the U.K is 31% 
and 29% for males and females respectively(56). Latest figures show that, in 
Liverpool, 26.6% of childhood males are overweight or obese, whilst 31.4% of 
childhood females are overweight or obese(76). Perhaps most startling is the 
prediction made in the Foresight report that suggests childhood obesity 
levels could rise from current levels of 7% to 26% by 2050(58). Furthermore, 
there are predictions that the future cost to the NHS of weight related 
disease could rise from £7.1 billion (annual cost in 2001) to £22.9 billion by 
2050. The huge health, fiscal and wider societal effects of this escalating 
problem are simply astonishing. The rapid global increase in obesity 
prevalence, along with the severity of its pathological consequences, has led 
to many scientists coining the term ―globesity‖(71).  Thirty percent (30%) of 
adult obesity starts in adolescence. Unsurprisingly, it has been  
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comprehensively stated in medical literature that being overweight in 
childhood or adolescence leads to a high risk of being overweight or obese in 
adulthood(77). Such ‗tracking‘ (an epidemiological focus on ill health over 
time) is certainly apparent for obesity. Moreover, morbidity due to obesity is 
occurring even in the childhood years. It is estimated that 80% of obese 
adolescents have elevated blood pressure(78) and 25% of obese children are 
predicted to have impaired glucose tolerance(79). There is also emerging 
evidence that obesity may cause increased risk of childhood asthma(80, 81) 
and sleep apnoea(82, 83), thus the focus on paediatric obesity prevention is of 
paramount importance to national health(84). This is not solely necessary to 
prevent later onset of pathology, but to tackle the morbidity it is causing in 
childhood. 
 
1.2.3 Pathophysiology of obesity 
 
A comprehensive review of obesity pathophysiology and its sequelae is 
beyond the remit of this thesis. There are, however, some fundamental 
concepts, and important new findings in obesity, that must be addressed 
before focusing on the specific aspect of obesity pathophysiology that this 
study intends to research. 
 
Figure 1: Overview of energy balance (used with permission from University of 
Liverpool School of Psychology department) 
 
 
 
 
 15 
In essence, the weight of an individual is dependent on their energy balance. 
Energy balance is the long term balance between energy intake (EI) and 
energy expenditure (EE)(85). This is summarised above in figure 1. There 
are numerous factors that contribute to each. Energy intake is controlled in 
part by the central nervous system (CNS). The CNS has control over feeding 
behaviour, and over the neuroendocrine system, which has both short and 
long term effects. In the short term, release of factors such as cholecystokinin 
and a myriad of other factors cause the feeling of satiation; a crucial factor in 
one‘s portion size. More long-term neuroendocrine factors such as leptin 
(explained in detail below) are released in levels correlated to the body‘s fat 
storage(85). There are a multitude of other central neural circuits that help 
control energy intake. Neuropeptide Y causes markedly increased appetite 
whilst the central melanocortin pathway can have a huge number of 
influences on energy intake. A comprehensive review of such pathways is 
beyond the remit of this thesis(85). The effect of single gene defects (as 
discussed below) on these aforementioned systems, and others, can alter 
energy intake. It must be noted that there is currently great focus on the 
genetic aspects of obesity. It has been argued, however, that these cannot be 
the main cause of the obesity epidemic, with significant changes in human 
genetic makeup unlikely to have occurred in the last two decades(86). Diet is 
another large factor in energy intake. There is an argument that increases in 
readily available, cheap, high fat foods, which are highly palatable foods and 
often in large portions, have had huge influence on the increasing prevalence 
of obesity(87-89). Factors that effect energy expenditure include exercise 
levels, purported to be lower in modern society(59, 90). Furthermore, 
thermogenesis is crucial to energy expenditure. There are two areas of focus 
in thermogenesis. Firstly, there is much study of the neural pathways that 
control thermogenesis, i.e. the autonomic system.  Secondly, the has been a 
focus on the area of thermogenesis at the cellular level(85). Beyond these 
conceptual large umbrella areas of energy intake and expenditure, there are a 
plethora of other factors that have an influence on weight, such as intra 
uterine pathologies, birth weight, ethic origin, sleep and endocrine disorders, 
amongst others(59).  Some factors have an effect on both energy intake and 
energy expenditure; for example socioeconomic status(59). 
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One theory regarding weight gain is that susceptibility to weight gain is 
associated with behavioural risk factors. There are behavioural risk factors 
for both energy intake and energy expenditure. Whilst behaviour controls a 
proportion of energy expenditure, it has been argued that it has a greater 
role in energy intake(91). This concept of behaviour affecting energy intake 
will be focused on in chapter 1.3. 
 
As aforementioned, a comprehensive review of factors influencing obesity is 
beyond the scope of this thesis. Certain aspects relevant to this thesis will 
now be focused on. There have been important genetic discoveries related to 
obesity in the past decade. The chance of an individual becoming obese when 
they have an obese relative is estimated to be between 30 -70%(92). The 
discovery of obese related genes is potentially the most fruitful avenue for 
successful treatment of this worldwide health concern. There can be no 
doubt that genetics are crucial to an individual‘s susceptibility to becoming 
obese. Hitherto no gene has been discovered to be the sole ―obese gene‖. 
Unsurprisingly, it is more likely that there is a multifactorial interaction of 
many polymorphic gene products that are the key to the pathophysiology of 
obesity(92). Neuropeptide Y and uncoupling proteins are amongst a number 
of aberrant gene encoding factors that have been implicated in the 
aforementioned pathophysiology(93). 
 
There are, however, a number of monogenic gene variants that can cause 
profound obesity, congenital leptin deficiency to name but one. Leptin is 
usually secreted in adipocytes in the regulation of satiety. In congenital 
leptin deficiency, where no serum leptin is detectable, hyperphagia and early 
onset of obesity are caused. Whilst, from a population perspective, the 
profound effects of a monogenic deficiency is fascinating, for the majority of 
obese cases, obesity is due to the small, but appreciable, effect of multiple 
genes and to a greater extent, the individual‘s relationship with their 
environment(93). Recently the fat mass and obesity related gene (FTO) was 
discovered(94, 95). On average, individuals who possess this gene weigh     3  
kg more than those with low risk alleles. Recent work has shown that FTO 
exerts it influence phenotypically by affecting the person‘s appetite 
behaviour(96). This is an important finding, highlighting phenotypic effect 
 17 
being exerted on behaviour, rather than metabolism.  There is a great deal of 
hope that successful treatments for obesity are closer with the important 
discovery of such genetic developments. 
 
Although the discovery of these genes is crucial to the unravelling of 
pathophysiology of obesity, it has to be remembered that these genes have 
been shown to make statistically significant but modest increases in weight, 
not considerable enough to account for the current obesity epidemic. This 
leads to the suggestion that the environment and behaviour play a crucial 
role in obesity(95). It has long been argued that ―mechanization is an 
incontrovertible fact inherent to our social milieu(71)‖.  Motor transport and 
white goods (e.g. washing machines) have reduced the possibility of keeping 
a thermodynamic balance. Furthermore, sedentary leisure activities have 
replaced a great deal of outdoors activity in children and adolescents 
alike(71, 87). 
 
The concern with obesity is its end consequences on health. Greater 
adiposity in children and adolescents leads to greater cardiovascular 
mortality in adulthood(97). Paediatric obesity can cause polycystic ovarian 
syndrome, non alcoholic fatty liver disease, a number of cancers and, 
importantly, metabolic syndrome (hypertension, dyslipidemia, insulin 
resistance), which occurs in up to 50% of overweight individuals(98). This 
does not take into account the large social stigma and discrimination obesity 
carries with it(99). 
 
There can be no doubt that obesity is one of the most important problems in 
today‘s society; its negative ramifications are seemingly endless.  
 
1.2.4 Overview of relationship between migraine and obesity 
 
Recently, a relationship between migraine and obesity has been highlighted. 
A crucial part of the pathophysiology of migraine is the recently developed 
concept that a proportion of migraine sufferers do not have a static disease, 
but rather a sub-group have migraine transformation(100). This term means 
the progression of migraine from low frequency episodic headache leading to 
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high frequency episodic headache and finally to chronic daily headaches. This 
transformation may not just be clinical but also physiological, with 
progression to stroke a possible consequence(101-103). Thus, it has been 
accepted that it is crucial that risk factors for this form of headache are 
highlighted to control and remove them and hence ameliorate the potentially 
devastating effects migraine can have if left to progress. Recently it has been 
shown that a key risk factor for migraine progression in adults is 
obesity(100). Crucially, this is a modifiable risk factor, unlike age. One large 
longitudinal study has shown that overweight or obese adults are more likely 
to have migraine progression to chronic migraine, after adjusting for co-
morbidities and demographics(104). Another cross sectional study suggested 
a five times greater risk of chronic daily headache in the obese compared to 
normal weight patient(44). A sub-section of this study suggested that the 
odds of having frequent headache were 2.9 higher in the obese(44). A third 
study suggested that obesity is a strong risk factor for chronic migraine 
headache more than chronic tension type headache(100) and a fourth study 
suggested that there was a strong association between obesity and headache 
frequency(105).  
 
All four of these studies were conducted in the adult population and only 
three studies have been carried out to investigate if the link holds in the 
paediatric population. The first study found that females had four times the 
risk of being obese if they suffered from headaches(106). The second found 
that increased weight was linked to increased headache frequency(107). The 
third also found a significant correlation between increased weight and 
increased migraine frequency(108). None of the paediatric studies hitherto 
have been longitudinal; therefore no direction of association has been 
elucidated.  
 
There are a number of theories as to how migraine and obesity interact. A 
unidirectional cause may be part of the pathology, with chronic migraine 
leading to a more sedentary lifestyle, and migraine prophylaxis often leading 
to weight gain. Another link is the possible shared genetics between obesity 
and migraine. This is summarised in figure 2 overleaf.  
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Figure 2: Previously cited theories on the relationship between migraine and 
obesity (adapted from published work by Bigal et al(109)) 
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Appetite behaviours are one area of focus by certain obesity researchers. 
Recent evidence has shown that neurobiological mediators of inter-individual 
susceptibility to obesity act via appetite behaviour (94, 96, 110, 111). Willer 
et al have recently reported that the common genes involved in obesity are 
expressed in the central nervous system(111). The FTO single nucleotide 
polymorphism is expressed in the hypothalamus, which controls the 
behavioural aspects of appetite(110). FTO does not cause increased energy 
expenditure, further supporting the theory that FTO association with 
increases in BMI are mediated by appetite behaviour.  
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Recently, Wardle and colleagues highlighted specific eating behaviour using 
psychometric tools (the Children‘s Dutch Eating Behaviour Questionnaire 
(CEBQ)). In particular, focus was placed on satiety responsiveness and 
external eating/enjoyment of food. Furthermore, using the CEBQ measure, 
Wardle and Carnell identified that certain eating behaviours are associated 
with ‗adiposity‘, a state whereby patients are on the trajectory toward 
obesity(112). With important discoveries like the FTO gene, researchers are 
interested in the functional expression of such genes(96) i.e. the behaviour of 
an individual.  
Behavioural risk factors for energy intake include patterns of eating and 
preferences for specific types of foods. It has been previously argued that 
these behavioural risk factors are ―regarded as biological dispositions which 
create a vulnerability for weight gain and which manifest themselves 
through behavioural acts(113)‖.  
Work in appetite behaviour is suggesting that aberrant appetite behaviours 
can be associated (along with a myriad of other factors) with the onset of 
obesity and research into this is of paramount importance. If one learns how 
to interrupt this pattern of eating they can potentially arrest the progression 
to obesity. 
Reflecting on the increasing interest in appetite behaviours and referring to 
the neurobiological chapter 1.4 later in this thesis, it seems entirely plausible 
that certain neuropeptides, present in both migraine and obesity, are 
biological dispositions, which create vulnerability for weight gain, potentially 
mediated by appetite behaviours.  This is an argument for why migraine 
severity should be correlated with appetite behaviours. Plausibly, using the 
aforementioned theory, the more severe the migraine, the more severe the 
biological disposition to weight gain through behavioural acts.  
This study aims to focus on appetite behaviours in migraine patients. The 
relationship between migraine and obesity has been highlighted. But the 
direction of effect, and the underlying relationship is not clear. Theoretically, 
aberrant appetite may occur in migraineurs that lead to subsequent obesity. 
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1:2:5 Reflection upon alternative mechanisms in the relationship between migraine 
and obesity 
 
On reflection of the energy balance (figure 1) section earlier in this section, 
there are other mechanisms in which migraine could be associated with 
obesity. Regarding the energy expenditure side of the energy balance, it 
could be argued that migraine patients have a lower basal metabolic rate. 
Therefore a lower basal metabolic rate in this group would increase the 
chance of obesity. From a literature search there is no current work into this 
area to support this postulation in the migraine population. 
 
Alternatively, it could be argued that migraine patients expend less energy, 
putting them at higher risk of obesity. Research has shown that exercise can 
precipitate an migraine attack in a proportion of migraine patients(114). 
There is work suggesting that almost half of migraine sufferers experience 
exertional exacerbation of headache(115).  It could, therefore, be argued that 
certain migraine patients avoid exercise for fear of an attack. This adaptive 
behaviour would put them at increased risk of obesity. However, 
contrastingly, there is also evidence that regular exercise reduces migraine 
frequency and severity(116-119). Of course it is still plausible that due to the 
general perception that exercise exacerbates migraine, migraineurs avoid 
exercise, in spite of its supposed benefits.  
 
Similarly, research has shown that over 80% of chronic migraineurs suffer 
from fatigue(120). This fatigue could potentially reduce a persons desire 
and/or ability to exercise, again putting them at increased risk of becoming 
obese. The only current study addressing exercise levels in the paediatric 
migraine population found that migraineurs do more exercise than their 
migraine free peers(121). It is clear that exercise in paediatric migraineurs 
has not been thoroughly studied. It must also be noted, however, that in a 
recent study, the basic paradigm that physical inactivity causes obesity has 
been called into question. In a longitudinal study of a general paediatric 
population it was found that physical activity was not predictive of changes 
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in body fat percentage(122). Conversely, body fat percentage was predictive 
of changes in physical activity. Essentially, this is the reverse causality of the 
generally accepted concept that physical inactivity leads to obesity. This is an 
important finding that challenges this idea that minimal exercise, a large 
facet of energy expenditure, is integral to weight gain. This re-directs the 
focus upon the energy intake side of the energy balance. This is strong 
support into the justification of a novel study addressing appetite behaviours, 
one aspect of energy intake. That being said, further work is needed in this 
area before firm conclusions can be made. It is still plausible that the 
relationship between migraine and obesity is mediated by a reduced energy 
expenditure due to poor exercise levels.  This is potentially as likely as the 
relationship between migraine and obesity being mediated by appetite 
behaviour on the energy intake side of the energy balance (Figure 1). Further 
study would be entirely worthwhile to research the effect exercise patterns 
have on the relationship between migraine and obesity. 
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Chapter1:3 What are appetite behaviours? 
1.3.1 Appetite Behaviour 
The review of obesity highlights that it is a global issue that has great impact 
on health. The strong influence of genetics on this condition is 
incontrovertible, however, the high increase in obesity levels over the last 
twenty years suggests other key factors are involved in the disease. The 
‗obesogenic environment‘ is well cited in the literature as having a large role 
in recent obesity levels. Increasingly sedentary lifestyles, associated with 
readily available and widely advertised high fat, high sugar and energy dense 
foods at affordable prices are a huge part of the environmental influence. One 
analogy has proposed that ‗genes load the gun, but the environment pulls the 
trigger‘(123). 
 
One issue with the current crisis of obesity is the fact that there remains such 
a great deal of variation in the population exposed to the same ‗obesogenic 
environment‘. One theory is that there is an inter-individual susceptibility to 
obesity that is, at least in part, mediated by variation in appetite 
behaviours(88, 110). 
 
Aberrant appetite behaviours are when an individual‘s appetitive traits 
increase their susceptibility to obesity in their environment(112). A simple 
example is if an individual has poor satiety responsiveness, whereby an 
individual responds poorly to their internal satiety signals and therefore eats 
a greater amount of food(124, 125). There are many psychological theories of 
appetite behaviour surrounding food cravings that are triggers for 
overeating. The appetite behaviours literature is extensive. It must be noted 
that all aberrant appetite behaviours do not occur exclusively in the obese; 
they can also occur in people of normal weight; for example binge eating, 
exhibited in bulimia nervosa, does not necessarily mean a person will be 
overweight. 
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One theory hypothesises external eating as a key aberrant eating behaviour. 
It suggests that certain people are more sensitive to external food cues than 
others and eat in response to those environmental stimuli, irrespective of 
their internal signals of hunger or satiety. It is suggested that favourable 
environmental cues, such as smells or signs, can cause large food cravings 
and drives for food even when fully satiated(126). 
 
An overlapping concept to this is the idea of food cue responsiveness. Greater 
food cue responsiveness can mean all manner of things. It can mean 
responding more to highly palatable appearing foods, responding to foods 
physically visible or responding to time cues e.g. ‗lunch time‘ rather than 
satiety cues(127). The hypothesis of eating in the absence of hunger in 
response to food cues has been shown in the paediatric population(128). Food 
cues are often measured in ingestive laboratories. They are considered 
demonstrable, observable appetite behaviours. For example, ten minutes 
after eating to satiation in an ingestive laboratory setting, children were left 
in a room with highly palatable looking foods (chocolate, crisps, sweets) and 
obese children were shown to override their satiety signals to a greater 
degree than lean controls, exhibited by the obese subjects eating more 
food(128). Note the similarity between the two appetite behaviour theories of 
external eating and food cue responsiveness; both propose that certain people 
respond to the physical presence of foods, in particular, attractive, highly 
palatable appearing foods.  
 
A more recent theory, a component of the theory of ―the power of food(129)‖ 
focuses on the effect that the presence of food has on appetite(129). This 
concept overlaps with the idea that the proximity of food physically alters the 
person‘s relationship with that food. In other words, if the food were 
available, but not directly in front of them, they would act differently i.e. not 
search out the food to eat. A subtle difference of this concept from the former 
two, is that it is trying to assess the effect that living in a food abundant 
environment has on appetite, rather than assessing if someone overeats in 
this environment(129). The theory of the power of food can be seen to be the 
flip side of food cravings (mentioned in detail below). Power of food is 
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focusing specifically on the effect of food in close proximity on a person‘s 
relationship with food. Conversely, food cravings highlight a person‘s 
cravings for a specific food, in the absence of that food. 
One more component of the theory of the power of food is food availability.  
This is associated with the current abundance of food to which much of the 
developed world is exposed. It has been postulated that because there is such 
wide spread availability of food, not necessarily in close proximity, but easily 
accessible, that this alters a person‘s appetite behaviour(129). 
 
Another concept is that of the restrained eating theory. This theory suggests 
that dieting can cause excessive weight through bingeing. People who diet 
suppress their feeling of hunger cognitively and eat less. These cognitions 
are undermined (disinhibition), however, with high food cravings causing 
disinhibition and binge eating, restrained eaters are more likely to overeat 
than non dieting individuals; known as ‗counter – regulation‘(130). Recently, 
this theory has been developed in another tool(131), which splits restraint 
eating behaviour into rigid and flexible cognitive restraint. Rigid cognitive 
restraint is where an individual has an all or nothing approach to eating food, 
and when trying to reduce food intake does so in a strict and meticulous 
fashion. It is this rigid approach most likely to result in diet breakdown(131).  
 
Emotional eating is another theory of appetite behaviour; it suggests that 
some people eat in response to their emotions, not to internal signals such as 
feelings of hunger or satiety.  In the case of emotional arousal or stress, 
strong food cravings cause emotional eaters to respond by eating 
excessively(132). 
 
Emotional eating, and external/food cue responsiveness/food presence are 
arguably associated with a recent, distinct, and evolving concept in appetite; 
that of hedonics (discussed below) in eating. The link of emotional eating 
with hedonics is that emotional eaters are purported to be stimulated to eat 
due to low self-esteem, thus it could be suggested that, in seeking food, they 
are seeking pleasure from eating palatable foods(133, 134). The link of 
external eating with hedonics is that arguably visible foods are only so 
attractive and desirable if they offer some satisfaction or pleasure(134). 
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1.3.2 Hedonic versus Homeostatic mechanisms of appetite 
 
There is evidence that certain groups of patients have a heightened hedonic 
response to food, i.e. a hyper-responsiveness to the sensory properties of 
food.  It has been previously shown that these hedonic drives can override 
physiological satiety signals (135). Put simply, people can eat high density, 
highly palatable foods when they feel full. A study previously showed that 
when participants had to rate the pleasantness of the high fat food they were 
eating, those who rated the food highest had the greatest adiposity. The 
more overweight the participant, the more they enjoyed the food (136). 
A crucial emerging behavioural neuroscientific concept is that of ‗liking‘ and 
‗wanting‘ that mediate physiological processes. Liking is suggested to be 
simply the hedonic response of a stimulus(134). The hedonic response is the 
brain‘s reaction to a pleasurable sensory stimulus. A simple example is the 
enjoyment/pleasure experienced whilst eating a sweet. In contrast, wanting 
is the behavioural incentive aspect of the same stimulus. To be clear, wanting 
is not the hedonic response to the stimulus. Rather, it is the drive or pursuit 
of a stimulus(134). Hedonic drive is a new theory that contests the classic 
concept of homeostatic drive. Homeostatic drive is the concept that there is a 
stable internal state. That there is a set point that is regulated whereby 
maintaining a stable physiological state. When reflecting upon appetite, this 
may well be seen to support the homeostatic theory, because the body should 
theoretically have a plethora of set points for nutrients and deviation from 
these leads to hunger and, of course, when nutrients are sufficiently ingested 
satiation occurs(134). Conversely, a criticism of this theory is that there is 
unlikely to be set points for hunger, but rather likely more fluid ‗settling 
points‘ that are influenced not just by internal satiety signals but external 
factors such as availability and palatability of food and also the eating 
behaviours of the individual(137). 
The hedonic concept transcends simple regulatory set points, and rather 
suggests there are motivational behavioural drives created in the brain for 
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stimuli. The arguments of the need for research into fresh behavioural 
concepts and the shortcomings of the classic homeostatic regulation concept 
are beyond the remit of this thesis. Safe to say, the hedonic behavioural 
concept is evolving with pace.  When this is applied to appetite, wanting can 
manifest as cravings for particular food types. These are often highly 
palatable, high calorie, highly pleasurable foods; thus food cravings have a 
role in the concept of hedonic physiological drive rather than homeostatic 
physiological drives(138). It should be noted, however, that hedonic and 
homeostatic mechanisms are not mutually exclusive when referring to 
appetite. The high palatability of food can produce a hedonic response which 
delays the onset of satiety(134). It will, therefore, be important to map out 
food cravings in this study, in order to address the particular ‗wanting‘ or, 
food cravings of migraine patients. Food cravings have informally been 
studied in migraineurs, but not in the context of rigorous appetite behaviour, 
and will be reviewed in a later section(1.3.5). 
Other concepts overlap with the umbrella term of hedonics in appetite. 
Firstly, food reward(139), a less well-researched appetite behaviour in the 
paediatric population, overlaps with hedonic appetite. The hypothesis 
suggests that obese individuals experience a greater subjective reward from 
consuming highly palatable, high-energy foods(127). It has been shown, in 
an ingestive laboratory setting, that obese individuals will work for longer 
on a computer task to gain a palatable reward than lean individuals(140). 
Thus food reward suggests that if obese individuals work harder for these 
rewards, this is potentially because they experience greater reward, 
presumably through enjoyment or pleasure of eating, be it the sensory aspect 
or another aspect. Secondly, another power of food concept is that of ‗food 
tasted‘(129). This focuses on how certain people focus on the pleasure and 
enjoyment of the food they eat(129). Thus hedonics can be seen to encompass 
these two concepts. 
 
Another area linked to hedonics, and even to food cravings, is food 
preferences(141). Essentially the premise of this concept is that people have 
preferences for high-density foods (fats) as opposed to low-density foods 
(fruit and vegetables). This can also been seen to be linked to the hedonics of 
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appetite. It has been shown that overweight adults have higher energy 
density diets than people of normal weight (142). Hitherto, the liking and 
wanting of high density foods in this group have not been comprehensively 
shown(127). It would, however, presumably follow that those who have food 
cravings for highly palatable foods are those most likely to eat such foods. 
 
Another important appetite behaviour is satiety responsiveness. This is 
essentially how an individual responds to internal satiety signals. In the adult 
literature it has been shown that obese patients have a lower satiety 
responsiveness compared to lean controls(124). Similarly, in an adolescent 
population, in an ingestive laboratory setting, obese children did not exhibit 
any downward regulation of their intake to a test meal, offered immediately 
after a preload meal, compared to lean controls(125). This is but one example 
of how children with greater adiposity show weak satiety responsiveness, 
whereas, strong satiety responsiveness is based on the theory that an 
individual who is responsive to his/her internal satiety signals will reduce 
food/energy intake in response to their preload intake(112). The normal 
adaptation to reduce intake after an energy dense preload has been coined 
‗energy compensation(127)‘. In addition to energy compensation, another 
suggested good indicator of satiety responsiveness is eating rate. It is 
presumed that if an individual‘s eating rate slows it is a response to internal 
satiety signals(139). Once more in the elder paediatric population, in an 
ingestive laboratory setting, it was shown that obese children continue to eat 
at the same rate compared to lean controls(143). 
 
It is clear to see there is a plethora of different concepts, theories and 
theorists regarding appetite behaviour. It is important to highlight that 
certain appetite behaviours have been linked to the inter-individual 
variability of response to environmental cues causing a variation in risk of 
weight gain(126). Thus one plausible mechanism for the variation of weight 
is the individual variation of appetite behaviour expression in the population. 
 
It has recently been shown that children‘s appetite behaviours are consistent 
over time(144). Striking continuity was shown in a prospective study of over 
four hundred children analysing seven different subscales of their appetite 
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behaviour over eight years. This is a crucial finding for this proposed 
research. This study hypothesises, as aforementioned, that severe migraine 
leads to aberrant appetite behaviour, which, in turn, leads to increased 
adiposity. Thus, by capturing children at migraine diagnosis, the study hopes 
to elucidate whether children at the severe end of the migraine spectrum, will 
have the poorest/most aberrant appetite behaviour, which puts them at 
highest risk for increased adiposity. The finding that children‘s appetite 
behaviours are consistent further supports the plausibility of the hypothesis 
that poor appetite behaviours are strikingly consistent through childhood 
into adulthood. 
 
Overleaf is a schematic overview (Figure 3) of all the discussed appetite 
behaviours. The solid arrows represent the close associations already 
discussed between certain appetite behaviours. The 3-D blocks represent 
distinct appetite behaviours on each face that has theoretical overlaps with 
one another. The dotted lines are hypothetical associations between migraine 
and the different appetite behaviours, which the study aims to identify.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 30 
 
 
 
 
Figure 3: Overview of interrelationships between appetite behaviours and their 
potential relationship with migraine 
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1.3.3 Aspects of appetite that have already been studied in migraineurs  
 
1.3.4 Dietary triggers of migraine 
 
By far the most widely documented component of diet in migraine is the 
discussion of foodstuffs that trigger migraine. It has long been suggested 
that certain foods precipitate the onset of a migraine. Although not strictly 
relevant to this study, it is the largest volume of literature on diet in 
migraine. It is very common for migraine patients to avoid certain foods 
based on what they have been told from varying sources of differing rigor. 
This behaviour is undoubtedly related to the appetite behaviour aspect of the 
proposed study. 
High levels of caffeine ingestion (often caffeinated soft drinks are consumed 
by children) with subsequent sudden abstinence can cause withdrawal 
headache and exacerbation of migraine can ensue. The pathophysiology of 
this trigger is that caffeine intake causes vasoconstriction and a rebound 
vasodilatation and there can be an increase in blood flow when caffeine intake 
is arrested(145). 
Cheese is commonly suggested to be a food trigger, due to the high 
concentration of tyramine it contains(146). The high levels of tyramine cause 
a vasoconstriction secondary to noradrenaline release(147).  
Chocolate is another foodstuff that can trigger migraine. A number of 
ingredients could be the trigger (Refer to table 1 below). Again, any of these 
substances could precipitate headache by alteration of cerebral blood flow 
and/or release of noradrenaline(148).  
Alcoholic drinks are a possible substance to trigger migraine (refer to table 
1) in adolescents. The pathways in which these chemicals induce a migraine 
are multiple: amongst others tyramine, as aforementioned, releases 
noradrenaline and histamine releasing nitric oxide from the vascular 
endothelium(146, 149). 
 
 
 32 
A discussion of the less well-described food triggers is beyond the remit of 
this thesis, but note table 1. Amongst other triggers, nitrites, in a lot of cured 
meats, have been cited as causing migraine, theoretically by nitrites acting on 
the endothelium causing vasodilatation(148). Monosodium glutamate can 
induce migraine in a very small proportion of migraineurs. Aspartame, 
frequently used as a sugar replacement, has been associated with triggering 
headaches, as have fatty foods(146). 
Irrespective of whether dietary advice has been given at a primary care level, 
or simply colloquial advice, dietary triggers are well known by migraine 
patients; they are commonly discussed in migraine clinics as part of optimal 
management.  
Food neophobias are defined as the rejection of foods unknown to the child 
(150). In contrast, food avoidance is avoiding a great deal of known or 
unknown foods resulting in a habitual diet characterized by a low variety of 
foods. Whilst the former is an inherent adaptive human trait, the latter is an 
aberrant behaviour(150). Great deals of dietary triggers are known in 
migraine, and patients cite a great deal more. It will be important to elicit 
within appetite behaviours if there are any particular foodstuffs that patients 
avoid, and whether they have reasons for doing so, such as known triggers or 
allergy, or advice from a health care worker or layperson. If certain foods are 
avoided this needs to be highlighted in results. Certain avoidance, whether 
founded or not, will have an influence on appetite behaviours and it is 
essential this is duly considered. 
 
 
 
 
 
 
 
 33 
Table1:  Dietary triggers in migraine(146): 
Food type Theoretical chemical trigger of 
migraine 
Cheese Tyramine 
Chocolate Phenylethylamine, Theobromine 
Citrus fruits, Phenolic amines, Octopamine 
Meats (hams/Cured meat) Nitrites, Nitric oxide 
Dairy products Allergenic proteins (casein etc) 
Fatty foods Linoleic and oleic fatty acids 
Snack foods, Eastern foods Monosodium glutamate 
Coffee, tea, coke Caffeine withdrawal 
Food dye additives Tartrazine, Sulfites 
Artificial sweetener Aspartame 
Alcoholic drinks (wine, beer) Histamine, tyramine sulfites 
Fasting Stress hormone release, 
hypogylcaemia 
 
 Table one is a summary of the established triggers of migraine and the 
theoretical chemicals within each substance that is thought to be the cause of 
the trigger,  
1.3.5 Food Cravings in migraine 
Blau (151) informally recorded the eating patterns of migraine patients 
around the time of their migraine attacks. He highlighted that a subset had 
substantial cravings for certain foods. In particular, a pattern of cravings for 
starchy, carbohydrate based foods was classic (151). The methodology of this 
study was very informal, with researchers simply directly asking the 
participants if they could eat around the height of their headache, and if so, 
what foods they ate, if they had any specific cravings, and if they had any 
accompanying nausea. 
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In another study by Dalton, whilst trying to highlight specific triggers for 
spontaneous migraine attacks, it was found that 67% of patients had fasted in 
the previous twenty four hours. These two studies highlight that there may 
be a role for appetite behaviour in the pathophysiology of migraine. Both 
studies focused on issues around the time of attack. The aim of this study is 
to design and conduct a more formal study focusing on whether trait 
migraine affects trait appetite behaviours i.e. the day-to-day appetite traits of 
a migraine sufferer, not their appetite around attack.  
1.3.6. Migraine medication and appetite 
It is well documented that certain migraine medications cause alteration of 
body weight. Pizotifen causes weight gain in children, irrespective of their 
previous weight and irrespective of the dose(152). It has been suggested this 
is due to the role of the serotonergic system on appetite.  Conversely, 
Topiramate treatment causes substantial weight loss(56), irrespective of 
previous BMI. These side effects are important, impacting on clinical 
management. For example, changes in appetite and weight can lead to poor 
compliance and discontinuation of pharmacological therapy. Ingestion 
laboratories or psychometric tools have not formally studied the mechanisms 
of medication related weight change hitherto. 
The aim of this study is to identify the pattern of appetite behaviours in 
children with migraine. The study will focus on the children‘s stable eating 
behaviours, i.e. their eating behaviour ―traits‖ between acute attacks(151). 
The aim of the study is to focus on this rather than their appetite behaviours 
around the time of attacks, i.e. the ―state‖ appetite behaviours. Eating 
behaviour around the time of migraine attacks has received attention in 
previous studies with patients reporting specific cravings (e.g. chocolate and 
carbohydrates) prior to the onset of an aura of migraine, although 
standardized measures were not used(151). Blau et al showed that missing 
meals could induce an acute attack in migraineurs(153). Both migraine and 
obesity are stable traits i.e. chronic conditions, therefore this study will focus 
on the trait eating behaviours since the intention is to identify chronic eating 
behaviours which, in other literature, has been associated with increased 
adiposity(132). 
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Patients with migraine were studied to see if they had eating disorders and 
88% of the female population did have eating disorder. This is much higher 
than the general population. Of importance, the majority (56%) stated 
migraine had preceded the onset of their eating disorder. This is crucial in 
suggesting that migraine causes aberrant appetite behaviours, irrespective of 
their subsequent clinical manifestations. These patients are supposedly 
under-eating as a result of migraine rather than over-eating. This begs the 
question whether the relationship between migraine and appetite occurs at 
both ends of the appetite spectrum. Can migraine cause aberrant under 
eating as well as overeating? Is there a non-linear association to this 
potential relationship? 
1:3:7 Other chronic pain syndromes and appetite 
 
In stark contrast to this study‘s hypothesis, a study of chronic pain in an 
elderly population highlighted a self-reported appetite impairment(154). This 
suggests that chronic pain, be it migraine or another pathology, actually 
leads to reduction in appetite, the opposite of this study‘s hypothesis. Whilst 
this is worth note and consideration, the author of these findings suggests 
much greater work is needed to establish any casual relationship between 
chronic pain and diminished appetite. Furthermore, the population is at the 
other end of the age spectrum, so not strictly transferable to this planned 
study. A further study of children and adolescents with chronic pain (caused 
by a wide spectrum of pathology) showed that 51.1% had problems attributed 
to eating. This suggests that chronic pain may cause an appetite reduction in 
child sufferers, contrary to this study‘s hypothesis. Furthermore, the 
majority of participants that reported appetite loss were migraine 
participants. At this point, a conceptually important distinction has to be 
made. On first considering this result it appears to completely contradict this 
study‘s hypothesis, however, appetite loss around the time of migraine 
attacks, as is reported in this study(155), is well cited. Over 82% of migraine 
sufferers have been shown to be anorexic around the time of attack(156). 
Thus, in this light, these findings are somewhat unsurprising. This study‘s 
hypothesis is focused on migraineurs trait appetite behaviours, i.e. their 
chronic appetite behaviour, outside of attacks. The aforementioned study, 
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although focusing on chronic pain, is reporting migraine sufferers‘ appetite 
behaviour around the time of attack. Recent work on rats has shown that 
appetite is maintained in the face of chronic pain. The study highlighted, 
that, when being stimulated with sustained noxious stimuli appetite did not 
alter(157). 
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Chapter 1:4 The neuropeptides that underpin the 
neurobiology of migraine, appetite and obesity: 
 
It is important at this point to review the neurobiology that underpins the 
plausibility of the relationship between migraine, appetite and obesity. 
 
Chapter 1:4:1 Calcitonin Gene Related Peptide 
 
Calcitonin gene related peptide (CGRP) has been shown to be a key link 
between migraine and obesity, with levels being higher in both pathologies. 
CGRP(158) is a 37 amino acid neuropeptide, which was discovered twenty 
years ago. There are two forms of CGRP, CGRP and CGRP; varying by 
only three amino acids, they have identical effects biologically on 
vasculature(159). CGRP possess a wide number of functions within the 
central and peripheral nervous system(160). Importantly, CGRP is 
synthesized and stored in the trigeminal ganglion neurons(161). It can be 
released when trigeminal ganglion neurons are stimulated(162), which, 
crucially, causes potent vasodilatation of the cranial blood vessels(160). It has 
been shown that CGRP is implicit in the pathophysiology of the onset of 
migraine(163). Studies have shown that CGRP levels are elevated during a 
migraine attack(164, 165). 
 
Moreover, it has been shown that an infusion of CGRP induces a migraine 
attack in migraineurs(163). Furthermore, arguably the most important 
experimental data linking CGRP to migraine, is two extensive RCT‘s that 
successfully trialled CGRP antagonists to reduce migraine severity(166). 
Two pharmacological CGRP antagonist agents reduced migraine attacks 
significantly. Firstly, the CGRP antagonist BIBN 4096 BS was shown to 
significantly reduce migraine severity at 2 hours and at 24 hours compared 
to placebo(26). More recently, the CGRP antagonist MK – 0974 was shown 
to significantly reduce migraine pain at 2 hours compared to placebo. CRGP 
is instrumental in migraine pathology. 
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Plasma CGRP is elevated in obese patients(109). A study nearly two decades 
ago suggested that CGRP is intrinsically related to obesity in the female 
population(167). Rat studies show that CGRP is raised in the obese subjects 
prior to onset of obesity and becomes more elevated once obese(168). 
 
Thus, CGRP is a crucial neuropeptide in the theoretical framework for how 
migraine, appetite behaviour and obesity interrelate. It is clear CGRP is key 
in the underpinning of migraine pathology. It has been shown that CGRP is 
elevated in obese subjects, even before the onset of obesity. It fits in, 
therefore, with the theory suggested by Bigal et al(109) that migraine may be 
involved in the progression to obesity, as CRGP is elevated in migraineurs 
and is raised just prior to the onset of obesity, leading to its onset. Therefore 
migraineurs, with their higher levels of CGRP may increase the risk of 
obesity onset. The chronic rise in CGRP mediator can then lead to increased 
frequency and severity of migraine(109). The intermediary steps between 
migraine and obesity and severity of migraine remain unclear.  Irrespective 
of the neurobiological mechanisms, appetite traits are a physically 
demonstrable behaviour that could plausibly have a role in leading to obesity. 
These need greater focus, not least because this is the area that, from a 
preventative viewpoint, will need to be addressed. 
 
Chapter 1:4:2 OB Protein (Leptin) 
 
OB protein, commonly known as ‗leptin‘, is the product of the OB gene. The 
discovery of a mutation of the OB protein was a tour de force in the mid-
nineties(169). It was shown to cause hyperphagia in mice. Leptin is a 
polypeptide hormone secreted by adipocytes. Since the discovery of leptin, a 
plethora of work has shown that leptin undoubtedly has a role in appetite 
control(170). It has a multitude of roles; it is involved in regulation of feeding 
behaviour, metabolism and the autonomic nervous system(109, 170). 
 
Exactly how leptin interfaces with weight regulation remains unclear. Leptin 
levels certainly correlate with current levels of adiposity. The higher the 
level of fat deposition, the higher the concentration of leptin(171). It was first 
postulated that OB protein reduced food intake and increased energy 
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expenditure(172), hence it was named leptin; derived from leptos – Greek for 
thinness. It was shown that leptin directly acts upon OB protein receptors at 
the hypothalamus(173), thus a direct role in satiety seemed logical. High 
levels of leptin do not invariably reduce appetite or obesity, however(170). 
This suggests that there is potential leptin insensitivity at the level of the 
brain receptor, or alternatively, there may be a post receptor defect in CNS 
communication to appetite centres. This ambiguity demonstrates that 
leptin‘s role in appetite is unclear. 
 
Low leptin levels are linked to a high risk for the onset of obesity(170).  With 
regards to the proposed research, this is an interesting finding. It has been 
suggested leptin is involved in food seeking behaviour, the inner drive for 
foods, rather than satiety mechanisms. Thus, if leptin levels are low, a high 
food drive ensues and ravenous food seeking behaviour occurs, resulting in 
hyperphagia(170). 
 
This concept of leptin being implicated in food seeking behaviour is 
important to the neurobiological justification of this study. A recent case 
control study showed that leptin levels were significantly lower in migraine 
patients compared to healthy matches(174).  
 
Leptin is one of the key neuropeptides that justify this study‘s hypothesis. 
The migraine study above highlights that migraineurs have low leptin; 
therefore one mechanism in which migraine is a risk factor for obesity is by 
low leptin level mediation, as it can lead to aberrant hyperphagic food 
seeking behaviours. 
 
Leptin further highlights the biological overlap between migraine, appetite 
behaviour and obesity. When administered acutely, leptin causes 
vasodilatation and also has inflammatory properties. Both are well 
documented to have a large role in migraine pathophysiology(174). 
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Chapter 1:4:3: Orexins/Hypocretin 
 
Orexins are another class of neuropeptide, previously named hypocretin. The 
two types, Orexin A and Orexin B, are very similar molecules; they both 
interact with two receptors: orexin receptor 1 (OX1) and orexin receptor 2 
(OX2)(175). Subsequent to the confirmation that hypocretin has a role in 
ingestive behaviours, it was renamed ―orexin‖, which derives from the Greek 
word Orexis(176), meaning appetite. It was shown that administration of 
orexin to rats increased appetite and delayed the onset of satiety(177). 
Furthermore, administration of an orexin one-receptor antagonist reverses 
the norm, reducing appetite and hastening satiety(178). It was initially 
thought that orexins were focused on the lateral hypothalamus(179). It has 
since been established that orexin is involved throughout the CNS and its 
roles are diverse. Amongst other roles, it is integral in sleep/wakefulness 
patterns and the autonomic nervous system(180). 
 
With relevance to the prospective study, it is important that orexins have 
been shown incontrovertibly to be involved in regulation of appetite 
behaviour. They are involved in satiety signalling and are shown to increase 
food intake by prolonged feeding behaviour(176). 
 
There has been much research of orexin‘s role as an analgesic. Previous work 
has ―shown strong evidence for a role for orexin in the modulation of 
nociceptive processing(181)‖. In both mouse and rat studies orexin A had 
clear anti nociceptive properties.  These findings have relevance to migraine. 
Currently, the role of orexins in migraine has barely been investigated. 
However, a recent study by Sarchielli et al showed migraine patients had 
statistically significant higher levels of orexin in their CSF compared to 
controls(182).  The authors of this study suggest that these results should be 
interpreted as a neurobiological ―compensatory response to chronic 
pain(182)‖. In other words, there is an altered expression of orexin from the 
hypothalamus in response to chronic stress (due to chronic pain). 
 
Thus, in keeping with the hypothesis, this previous work all supports this 
study‘s hypothesis. If migraine causes a chronic stress on the hypothalamus, 
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this leads to increased levels of orexins, which subsequently can alter eating 
behaviours, causing increased food intake due to altered satiety signals, 
eventually leading to the onset of obesity. 
Hitherto, no direct studies have been conducted trying to link migraine and 
obesity using orexins as a common pathway(183). 
 
In an alternative concept, Bigal et al(109) postulated an indirect link between 
orexin and migraine. Low CSF orexin levels are found in the vast majority of 
narcoleptic patients, and migraine pathology has a higher prevalence in 
narcoleptic patients than in the general population. The biological hypothesis 
behind this being that low orexins cause a vasodilatation(109).Without 
formal study this concept is merely speculative. Nevertheless, it is clear to 
see orexin as an important neuropeptide that needs further investigation in 
migraine, and has a clear biological plausibility in this study. 
 
Chapter 1:4:4 Serotonin 
 
5-Hydroxytryptamine, or Serotonin (5- HT), is synthesized from the amino 
acid tryptophan by the enzyme tryptophan hydroxylase (TPH) into 5- 
Hydroxytryptophan that is then decarboxylated by the aromatic L –amino 
acid decarboxylase (AADA) into 5-HT(184). The second of the two isoforms 
of TPH, TPH2, is brain specific and is expressed exclusively within the raphe 
nucleus, which lies in the brainstem. The serotonergic system from the raphe 
nucleus has persuasively been implicated in migraine pathophysiology. It is 
important to note that, whilst this is true, there is conflicting data in the 
literature. Irrefutable conclusions have not been reached(185). 
 
There are a number of trends that have been elucidated. Firstly, and most 
importantly regarding this research study, serotonin levels have been 
demonstrated to be lower in migraine sufferers than non-migraine patients 
interictally. Furthermore, 5-hydroxyindoleacetic (5-HIAA), a metabolite of 
serotonin, is higher interictally in migraineurs than in non-migraine 
patients(186). To further support this, there is increased brain serotonin 
synthesis in migraine patients(187). 5-HIAA concentrations are increased in 
the cerebrospinal fluid of migraine patients, suggesting increased breakdown 
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of serotonin in the central nervous system(188). This work suggests that 
chronically, migraine is a state of relative serotonin deficiency. This has been 
further supported by recent neuro-imaging studies, which used 5HTTR 
ligands and found increased availability in brainstem 5-HTTR in migraine 
patients. This is consistent with decreased levels of 5-HT at the synaptic 
cleft, due to decreased synthesis and/or release(189). Lastly, physiological 
studies have shown that migraineurs, interictally, have increased intensity 
dependence on the amplitude of auditory and visually evoked potentials, 
characteristic of low 5-HT transmission(190). 
 
Serotonin has been linked to the state of being satiated. It has a role within 
meal satiation and also with the end state of post meal satiety(180). In rodent 
studies it has been shown that administering 5-HT or precursors, such as 
tryptophan, significantly reduce food intake and eating rate.  Moreover, 
drugs that increase release of 5-HT have been shown to reduce food intake. 
Examples include selective serotonin reuptake inhibitors such as 
Fluoxetine(170). Sibutramine, a serotonin and noradrenaline re-uptake 
inhibitor (SNRI) is also a licensed anti-obesity agent; it is in National 
Institute For Health and Clinical Excellence (NICE) anti-obesity guidelines, 
because it is an effective hypophagic drug.  Conversely, pharmacological 
agents such as p-chlorophenylalanine (pCPA) block the synthesis of 5-HT 
and increase food intake(170). It has been suggested that serotonin has a 
number of interrelationships with other endogenous peptides involved in 
satiety, such as corticotrophin releasing factor (CRF), cholecystokinin (CCK) 
and neuropeptide Y (NPY)(180). 
 
It is clear that serotonin is a pertinent neuropeptide in this study‘s 
hypothesis. High levels of serotonin reduce appetite, as shown by rodent and 
pharmacology studies. Low serotonin, however, causes increased appetite. 
Migraine is a state of chronic low serotonin. It follows then, that the low 
serotonin state created by chronic migraine would potentially lead to 
increased appetite in its sufferers. This is crucial to the plausibility of the 
planned study. 
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Table 2: Summary of relevant neuropeptides overlapping in appetite behaviour and 
migraine(109): 
 
Appetite:   = Increases appetite. 
 = Decreases appetite 
Migraine:  = Increased levels in migraine patients 
 = Decreased levels in migraine patients 
 
Factor/Hormone Appetite Migraine 
NPY   
Orexin - A   
Leptin   
Serotonin   
CGRP   
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Chapter 1:5 Aims of MPhil Study 
There are three key aims to this MPhil thesis as follows: 
1. Firstly to undertake a formal literature review of the relationship 
between obesity and migraine in both the paediatric and adult population.  
2. To design a pilot study to assess the relationship between migraine 
severity and appetite behaviour. 
3. Conduct the pilot study, to address the following questions: 
a) Feasibility of study design 
b) Feasibility of participant recruitment 
c) Utility of psychometric tools in addressing hypothesis 
      d)    Elucidate any relationship between increased migraine severity 
  and aberrant appetite behaviour by completion of study.  
 
Hypothesis of pilot study: 
The hypothesis tested was that an increase in migraine severity would be 
associated with in increase in aberrant appetite behaviour. 
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Chapter 2: Methods   
2:1 Methodology of formal literature search for previous 
studies into the area of migraine and obesity: 
To assess the current literature systematically a number of formal literature 
searches were performed in the embryonic stages of the MPhil. Examples of 
such searches are given below in figure 4 and figure 5. It must be noted that 
regular literature searches were continued throughout the conduct of the 
MPhil to ensure new relevant published work was not overlooked. 
 
Figure 4: Example of a search strategy using NHS health information resources: 
 
 
 
 
No Database Search term Hits 
1 MEDLINE migraine.ti,ab 19961 
2 MEDLINE exp MIGRAINE DISORDERS/ 19614 
3 MEDLINE obesity.ti,ab 79007 
4 MEDLINE exp OBESITY/ OR exp 
OBESITY, MORBID/ 
93835 
5 MEDLINE obesity.ti,ab [Limit to: (Age 
Groups All Child 0 to 18 years)] 
17778 
6 MEDLINE 1 AND 2 AND 5 [Limit to: (Age 
Groups All Child 0 to 18 years)] 
15 
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Figure 5 : An example of a search strategy using the University of Liverpool Search 
Engine: 
 
Search for "Any word=(migraine) And Any word=(obesity) 
And Any word=(paediatric)" found 1988 results 
 
Database Name Status Hits  
MEDLINE (Ovid) - 
RECOMMENDED 
DONE 0  
PsycINFO DONE 2 View 
ScienceDirect DONE 43 View 
Scopus DONE 1288 View 
Web of Knowledge DONE 115 View 
AMED - Allied and 
Complementary 
Medicine 
DONE 0  
CINAHL DONE 3 View 
Cochrane Library DONE 1 View 
ebrary DONE 492 View 
Intute: Medicine DONE 0  
Journals@Ovid Full Text DONE 44 View 
Combined Results 
First 152 
records 
1988 View 
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Chapter 2:2 study design overview: 
The proposed study is a pilot, cross-sectional questionnaire based study. 
Migraine patients will be recruited from the tertiary paediatric clinics at 
Alder Hey Hospital only. 
• Participants will be between 5 and 16 years old, and will include both sexes. 
• Participants will be new referrals to Alder Hey neurology department. This 
is necessary because new referrals will be a proxy for new onset of migraine, 
or at least an increase in severity and hence a change in the neurobiology of 
their migraine (and thus a potential change in their appetite behaviour). 
• Sample size: After two consultations with a statistician it was decided that a 
cohort of 90 participants would be appropriate, consisting of 60 migraine and 
30 other non-primary headache sufferers. This sample size was calculated by 
the statistician based on the statistical concept that for every psychometric 
tool being measured against migraine severity 10-12 participants would be 
needed to show an effect size. There are 5 psychometric tools being measured 
against the migraine severity predictor, therefore a sample size of 60 
migraine patients was deemed sensible. A control group of 30 was suggested 
by the statistician; because this was a pilot study and there were no similar 
studies in the area therefore the statistician decided there was a need for a 
control arm to the study.  
• Participants must be drug naïve, based on the consideration that some 
migraine medications alter weight (refer to treatment of migraine chapter 
1.1.7), and presumably, therefore, appetite behaviour. 
Inclusion criteria: 
Diagnosis of migraine based on clinical criteria by the treating paediatrician. 
The International Headache Society Classification developed for adult 
migraine (see Appendix A) will be used as an adjunct. 
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Exclusion criteria: 
•Under 5 years old 
•17 years of age or over. 
•Known presence of a secondary cause of migraine-like headache e.g. brain 
tumour. 
Methodology/psychometric tools: 
pedMIDAS    – routinely collected 
Dutch Eating Behaviour Questionnaire – Ages 12-16 – Child reported: 
The Children‘s Dutch eating behaviour Questionnaire Ages 7 – 12 – Child 
Reported: 
The Child eating behaviour questionnaire: (CEBQ) Ages 5 – 12 – Parent 
reported: 
The Achenbach Child Behaviour Checklist (CBCL) – Ages 4 – 18 - Parent 
reported: 
The Food Cravings Inventory (FCI) 5 - 16 yrs - Child reported 
Food intake questionnaire  (FIQ) 5 -16 yrs – Child reported 
Body Mass Index (BMI) – Height and weight collected by the neurology 
clinic nurse routinely 
2.2.1 Practicality of recruitment 
The primary investigator identified potential participants for the study by 
two methods. Referrals to the neurology outpatient department from another 
health care professional (hospital consultant or general practitioner (GP) etc) 
all have a referral letter that is managed by the relevant consultant‘s 
secretary. Therefore, all secretaries were made aware of the study and were 
to highlight any new headache referrals to the primary investigator. For 
completeness, the primary reviewer also read through all neurology referrals 
once a week.  
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Furthermore, the primary investigator would read through the notes of all 
the patients who had an appointment with a paediatric neurologist (who 
managed headaches) prior to clinic on the days of headache clinics.  
If a patient was identified to fit the criteria for study, the patient and their 
carer were approached regarding the study after their paediatric neurology 
clinic appointment At Alder Hey Children‘s NHS Foundation Trust 
Hospital. The study was discussed with the carer of the child, and an info 
sheet was given to the carer. The carer was then asked whether they would 
agree to be involved in the study, or whether they needed more time to think 
about the study. If they agreed to recruitment, they were then brought into a 
private room (allocated for the study), whereby consent and assent was taken 
from carer and participant respectively. The relevant psychometric tools 
were then applied to the participant and carer respectively, taking 30 minutes 
on average. The clinic nurse routinely collected participants weight and 
height; therefore the primary investigator also noted these. In the event that 
the carer was unsure whether to become involved in the study, the primary 
investigator simply asked whether they would mind being contacted about 
the study again? If they agreed, then their contact details were taken and a 
time to contact them was decided upon by the carer. If, upon further contact 
with the carer, they agreed to be recruited to the study, a date for them to 
attend the paediatric outpatient clinic was arranged. On this date the 
relevant psychometric tools were applied to the carer and participant in the 
same allocated private room. Recruited participants and carers were offered 
the opportunity to be sent the results of the study once it had come to 
completion.  Note that the primary investigator recruited every patient in the 
study.  
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Chapter 2:3 Preliminary investigation to assess 
hypothesis (See Appendix E): 
As a preliminary assessment of the designed hypothesis, relevant preliminary 
data of 45 patients was collected at the tertiary hospital neurological 
outpatients clinic. It was important to elucidate whether the study hypothesis 
had any scientific justification. Using routine clinical data the aim was to 
identify if the hypothesis could be supported by preliminary data before 
conducting a full pilot study. The data collected were from consecutive 
migraine referrals to the neurology department. 
Details of patient‘s height, weight and headache frequency were collected.   
From this data, BMI z scores were calculated and headache frequency was 
categorised into: less than four headaches a month, four to ten headaches a 
month and greater than ten headaches a month. These were used as a 
predictor of headache severity. The results are shown overleaf. 
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  Figure 6: Correlation of BMI z-score with headache frequency:  
n=45 
The results in figure 6 above show a trend of increased headache frequency 
being associated with increased BMI-z score. Note the outlier in the category 
4-10 headaches per month, due to a morbidly obese participant. The results 
suggest that increased headache severity is weakly positively correlated with 
increased adiposity. Although the results were not statistically significant 
(most probably due to the small sample size of 45 patients) the trend fits into 
the hypothesis and supports the need for further focus on appetite behaviour.  
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CHAPTER 2:4 Research Methodology:  
Chapter 2:4:1 The process of identifying the most suitable psychometric tools 
for the planned study and the details of each tool 
2:4:2 Measure of migraine severity 
To best assess the morbidity caused by migraine a tool was required which 
would measure both the frequency and severity of the headache, as predictors 
of morbidity. After a literature review a number of appropriate methods and 
psychometric tools were identified. The International Headache Society 
(IHS) scale(191) was one such tool; this was based on child activity whilst in 
attack.  This tool was not appropriate for this study, the purpose of which 
was to focus on overall trait disability of migraine, i.e. the disability the 
headache causes the child overall, not just when in attack. Alternatively, the 
number of rescue medications the child used could be set as a severity 
predictor. This was not considered an appropriate method of assessing trait 
severity. Primarily, because participants were going to be new referral 
headache patients, many of whom would not have been prescribed rescue 
medication and secondly, because the consequences of the migraine headache, 
such as fatigue, can last much longer than the headache itself. The number of 
GP visits has been used be a predictor of severity(47), however, much of the 
morbidity of migraine, such as fatigue and poor concentration, would not be 
captured by this method. 
Two further appropriate psychometric tools were identified, the paediatric 
migraine disability assessment score (pedMIDAS) and the headache impact 
test 6 score (HIT-6). The HIT-6 is a six-item questionnaire, which assesses 
the impact of the sufferer‘s headaches on their life. It assesses their ability to 
carry out usual activities, social functioning, their cognition and emotional 
distress(192). Scores range from 36 (lowest) to 78 (highest). A score of less 
than 49 equates to no or little impact, 50-55 reflects some impact, 56-59 
reflects substantial impact, > 60 reflects severe headache impact(193). HIT-6 
has been widely used as a tool to measure headache impact, but not for 
paediatric migraine. 
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The pedMIDAS is derived from the migraine disability assessment score 
(MIDAS), which is the most extensively used psychometric tool to measure 
the overall impact of headache on an adult patient in the previous 3 months. 
The pedMIDAS is also a 6-item questionnaire, which assesses headache 
disability during the previous 3 months. The tool records the impact 
headache has on school, home and social life. The number of days absence 
from school or social activity due to headache are recorded, as are the 
number of days on which headache causes participants to have at least 50% 
reduced ability in these settings or at home(11). PedMIDAS scores are the 
sum of the scores from the six questions, ranging from 0 to 270. A score of 0-
10 indicates no disability, 11-30 a mild disability, 31 – 50 moderate disability 
and a score greater than 50 indicates severe disability(11). 
Hershey et al have validated the pedMIDAS for its suitability in the 
paediatric population for which it was designed(11). The HIT-6 was costly 
and was designed for and validated in the adult population. In contrast, the 
pedMIDAS was a free tool to utilise and designed to be used in the paediatric 
population. Another potential questionnaire that was later discovered was 
the headache disability inventory. This questionnaire, however, is also 
targeted at adults and in the literature appears to have been superseded by 
the pedMIDAS. Another tool that could have been used to assess migraine 
disability was the paediatric Quality of Life measure. This tool, however, 
focuses only on the disability side of the migraine, not the severity and 
frequency of the migraine; a crucial part of the headache nature needed for 
our study. It was decided that the pedMIDAS was the optimum tool to 
measure the migraine severity in the planned study; it was designed for use 
in the paediatric population in contrast to the HIT-6. Furthermore it focused 
not just on the disability side of migraine, but the severity of migraine as 
well.   
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2:4:3 Measures of appetite behaviour 
As previously mentioned, the primary outcome of the study was to correlate 
appetite behaviour to migraine severity, therefore, it was essential to utilise 
well validated, appropriate, psychometric tools to measure both. From the 
literature review it was clear that the Dutch Eating Behaviour Questionnaire 
(DEBQ) was a widely used tool for assessing appetite behaviours in the 
behavioural psychology domain. The authors of this tool were also the 
authors of a number of appetite behaviour concepts mentioned in chapter 1.3 
and it was clear that this questionnaire was very relevant and would focus on 
the appetite behaviours in which we were interested.  
Dutch Eating Behaviour Questionnaire – Ages 12-16 – Child reported 
The Dutch Eating Behaviour Questionnaire (DEBQ) was developed by Van 
Strien et al in 1986(194). The questionnaire is completed by adolescents aged 
12- 16 years old. It has been shown to be straightforward for adolescents to 
use(195). It consists of 33 items, which measure emotional eating (eating in 
response to certain emotions to cope with feelings or improve mood), 
external eating (eating because of external triggers and cues to eat, such as 
presence of food, rather than because of hunger or other internal cues) and 
restrained eating (defined by concern for dieting and weight fluctuation, 
leading to overeating episodes). There are 13 items to assess emotional 
eating, 10 items for external eating and 10 items for restrained eating. Every 
answer is rated on a scale 1 (never) to 5 (very often). The DEBQ scales have 
high internal consistency, high validity for food consumption, and high 
convergent and discriminative validity. Cronbach‘s alphas have been shown 
to be 0.92 for emotional eating, 0.84 for external eating, and 0.92 for 
restrained eating(133). The DEBQ has been widely used in adolescent 
studies of eating behaviour and obesity. External scores are most expected to 
change. This is based on literature that suggests there are greater external 
cues to food in obese subjects. There should also be more response to 
external cues in migraine due to the neurochemical mediators such as orexin 
causing an increased drive for food, however, emotional eating has been 
correlated with the CBCL internalizing score in previous work(196). 
Furthermore, it is known that internalizing scores are correlated with 
migraine and may, therefore, be confounding. 
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Although the DEBQ has been shown to be appropriate in adolescents (12-16) 
another simpler questionnaire was needed for younger children. After a 
further literature search the Dutch Eating Behaviour Questionnaire for 
Children (DEBQ-C) was discovered. This discovery was very timely, as the 
DEBQ-C was only validated in 2008(195), so the planned pilot study would 
be amongst the first to use this validated tool. It was crucial that the DEBQ-
C was found, because it demonstrated that, in younger children, the normal 
response to stressors was loss of appetite, in contrast to the response of older 
children and adults who were prone to overeating.  
The Children’s Dutch eating behaviour Questionnaire Ages 7 – 12 – Child Reported 
The Children‘s Dutch Eating Behaviour Questionnaire (DEBQ-C) was 
designed by the authors of the DEBQ (194). It is a child-reported 
questionnaire designed so that a reliable age adapted version of the DEBQ 
could measure restrained, emotional and external eating in 7 – 12 year old 
children. The DEBQ-C has been extensively analyzed in an initial pilot study 
and in two subsequent large-scale studies (769 participants and 515 
participants respectively)(197).  It has been reported that reliabilities of its 
subscales ranged from 0.72 to 0.82. Furthermore, good internal consistency 
was shown. Cronbach‘s co-efficients were 0.80, 0.72 and 0.68 for emotional, 
restrained, and external eating respectively(194). Being a 20-item 
questionnaire (rather than 33 items in the adolescent cohort) it would be 
more likely to be completed by participants with a short attention span. This 
questionnaire has only recently become commercially available and there are 
no reports of its use other than by the authors. 
After a number of discussions with the appetite specialists it was decided a 
form of parent/carer reported psychometric tool for appetite behaviour 
should be sought, rather than solely rely on the accuracy of the participant‘s 
answers. Furthermore, in the case of children at the youngest end of the 
spectrum (as young as 5), it was felt that they might struggle to answer the 
questions accurately for a number of reasons e.g. not understanding the 
question or not being confident to answer a researcher. The Children‘s 
Eating Behaviour Questionnaire (CEBQ), found after a literature search, was 
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chosen as the parent reported psychometric tool, due to it‘s robust structure 
and validation(198). 
The Child eating behaviour questionnaire: (CEBQ) Ages 5 – 12 – Parent reported 
The Child Eating Behaviour Questionnaire (CEBQ) is a parent reported 
questionnaire designed to assess eating styles related to obesity risk in young 
children (younger than envisaged for the DEBQ and DEBQ-C). It was 
designed to capture individual differences in aspects of eating style. It is a 35-
item tool, with eight subscales. These are food responsiveness, enjoyment of 
food, emotional overeating, desire to drink, satiety responsiveness, slowness 
in eating, emotional under-eating, and fussiness. Cronbach‘s alphas have 
previously been shown to be 0.80, 0.91, 0.79,0.89,0.74,0.74,0.74 
respectively(139). The CEBQ is accepted to be a very useful tool in 
measuring eating styles for research into the early precursors of obesity, thus 
it is entirely relevant for this study(198). It has been shown to have high 
internal validity and test-retest reliability. The ability to analyze parents‘ 
reports of the children‘s eating will be very useful for the proposed study. 
The study includes the combined Satiety-responsiveness and enjoyment of 
food scales as used by Wardle et al in their study of the FTO gene(110). The 
study design also includes the self-report DEBQ-C and the parent report 
CEBQ in the children aged 7-12 years since it is not clear in the literature 
how these two scales overlap. 
Another area this study was interested in addressing, as a secondary 
outcome, was the cravings aspect of patients‘ appetite behaviours. As 
mentioned in the literature search, Blau et al informally studied cravings 
around the time of migraine(151). No trait cravings have, however, hitherto 
been studied in the paediatric population. If patients have aberrant appetite 
behaviours e.g. overeating, it is plausible that they will have cravings for 
particular foodstuffs. To give an example, it has been shown that 
schizophrenic patients have aberrant appetite behaviours and, furthermore, 
have a predilection for excessive consumption of high fat, processed 
foodstuffs(199). It is important, therefore, to highlight if migraine, another 
chronic disease, causes cravings for certain types of food. Following 
extensive discussion with behavioural psychologists in the area of appetite, it 
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was decided that the food cravings inventory was the most appropriate tool 
for the aims. 
The Food Cravings Inventory (FCI) 
The food cravings inventory (FCI) is another psychometric tool to be utilised 
as an indicator of the types of food that migraine patients crave (on migraine 
free days) and the degree to which they crave them. The FCI is a validated 
28-item self-report measure of general and specific food cravings(126). 
Cravings are defined as ―an irresistible urge to consume a specific food(200)‖. 
Participants rate the frequency of cravings over the past 30 days on a 5-point 
LIKERT scale ranging from 1 (not at all) to 5 (nearly every day). The FCI is 
composed of four conceptual factors (scales): (1) cravings for high fat foods 
(e.g. fried fish); (2) cravings for sweets (e.g. cake, chocolate); (3) cravings for 
carbohydrates/ starches (e.g. bread, baked potato) and (4) cravings for fast 
food (e.g. pizza, burgers). From this a total score is also calculated. Subscale 
scores can be calculated for individual items, with higher scores indicating 
more frequent cravings for a particular food category. The scales have been 
characterized by exploratory factor analysis and confirmed with 
confirmatory factor analysis. The reliability and validity of the FCI has been 
established(201). Furthermore, the high fat food scale has been found to 
distinguish obese from lean individuals. In a previous obesity study 
Cronbach‘s alpha coefficients showed cravings for: - 1) fats - 0.81, 2) sweets - 
0.83, 3) carbohydrates - 0.76, 4) fast foods - 0.70 (202). The inclusion of this 
tool in the study will help map particular cravings in trait migraine that may 
help elucidate areas that lead to aberrant appetite behaviours. 
Following discussions with behavioural psychologists in the field of appetite, 
it was decided it would be important to highlight what typical foods the child 
eats in a day. Two relevant psychometric tools were available; the food 
frequency questionnaire and the food intake questionnaire. The former 
enables estimates of nutrient intake whilst the latter records what foods the 
patient has eaten on the previous day. Whilst the food frequency 
questionnaire would give more data with regarding specific nutrition, this 
was not necessary for our study. Capturing the typical foods being eaten by 
migraine patients was the aim, therefore after discussion with one of the 
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authors of food intake questionnaire(203), it was decided the FIQ would be 
incorporated into the study. 
Food intake questionnaire 
The Food Intake Questionnaire (FIQ)(203, 204) is a self-administered patient 
questionnaire, which requires a 24-hour recall method. The questions relate 
to consumption of particular foods on the previous day. The basic stem 
question is ―Did you at any time yesterday eat any amount of…...(204)‖ 
followed by a list of food related items. The questionnaire has been used 
extensively in Liverpool(205, 206), in large populations of school children to 
produce large volumes of normative data. 
The FIQ has been shown to be highly validated and have good reliability. 
Reliability of the FIQ was assessed by comparing mean scores for each food 
group using Pearson correlation coefficients. All correlations ranged from 
0.41 to 0.76. Previous studies have shown that the FIQ should detect a 
change of +/- 10% in eating behaviour(203). There are two large scale 
studies, each carried out on more than 700 school children in Liverpool(205, 
206),  which produced normative data on patterns of what children eat.  
Psychometric tools used as outcome measure for secondary outcomes: 
Chapter 2.4.4 The Achenbach Child Behaviour Checklist (CBCL) – Ages 4 – 18 - 
Parent reported 
The child behaviour checklist (CBCL) is a commonly used parent-reported 
psychometric measure that assesses emotional and behavioural problems in 
children aged 4-18 years. The first part concerns social skills, participation in 
organizations, contact with friends, participation and skills in sports and 
academic performance ratings. The second part deals with emotional and 
behavioural problems classified as internalized or externalized. Internalized 
behaviour problems are those that essentially the child himself experiences; 
they include anxiety/depression, withdrawal, schizoid, and somatic 
behavioural problems. Externalized problems are overt in nature, with direct 
effects on others: they include delinquency as well as cruel and aggressive 
behaviour. The CBCL consists of 113 items, which are scored on a 3-point 
Likert scale to indicate how descriptive the items are of the child during the 
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preceding 6 months. There are two broadband scores representing 
internalizing and externalizing problems and 8 narrow band behaviour scales 
are used within this. The CBCL exhibits good reliability and validity. When 
previously used in a migraine cohort of 47 patients, maternally reported 
scores for internalizing behaviour were 57.18 (S.D 10.15) in migraineurs 
compared to 49.84 (S.D 8.83) in controls with a Cohen‘s effect size of 0.80; 
externalizing behaviour was 53.66 (S.D 10.09) in migraineurs vs. 49.87(S.D 
12.74) in controls with a Cohen‘s effect size of 0.24(197). When previously 
used in an obesity cohort of 155 children, obese patients had an 
internalization score of 58.9 (10.9S.D) compared to controls 53.4 (10.4 S.D) 
and externalization score of 52.6 (SD 10.6) compared to controls 48.1 (9.5 
S.D). This gave an effect size of 0.010 and 0.004 respectively. (207). For 
clinical use the scores of the CBCL are calculated into T-score cut offs to 
assess whether a patient is exhibiting a particular psychological trait. 
Alternatively, mean and standard deviation scores can be used and compared 
with normal population scores. 
Previously, test – retest reliability correlations were between 0.82 and 0.95 
for the eight subscales and 0.93 for the total problem score(208). This is a 
well-recognised tool used in routine clinical care at Alder Hey, and used in 
numerous studies of childhood migraine and eating behaviour, henceforth it 
is a logical tool to incorporate in our study to understand whether 
psychological factors are a confounder in the planned study. 
The final task was the design of an informal migraine pro forma, which was 
an adapted pro forma published in the book ―headache in Childhood and 
adolescence(209)‖, to capture and classify what type of migraine the patient 
had. 
As demonstrated above, great thought, discussion and time were spent 
trying to determine the optimum tools to address the hypothesis. In essence, 
the project lies not strictly within medical research, nor fully within 
psychological research and in consequence, the synthesis of both areas with 
appropriate tools was a laborious one. Once the appropriate tools were 
designed, a large number of drafts of protocol were designed. In total fifteen 
iterations of the protocol were drafted and, once completed, were submitted 
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to the local ethics committee and research and development department. The 
length of time for favourable opinion was considerably longer than 
anticipated, and is discussed in the limitations section (section 6.4) of this 
thesis. It is important to highlight that whilst the protocol design and ethics 
applications were taking place two studies were published assessing obesity 
associated with migraine severity in the paediatric population(106, 107). 
These publications highlight the timeliness of the planned study, as 
internationally this area is gaining focus and interest. Furthermore, it 
highlights the originality of the study design. Unlike the aforementioned 
studies, both focusing on correlating weight with migraine disability, the 
focus on appetite behaviour in the study was novel. 
 
Chapter 2.4.5 Summary of psychometric tools to be utilised in study 
All psychometric tools below were answered at a one off interview with the 
participants: 
PEDMIDAS    – Measures headache severity 
Dutch Eating Behaviour Questionnaire – Ages 12-16 – Child reported – 
Measures appetite behaviours 
The Children‘s Dutch eating behaviour Questionnaire Ages 7 – 12 – Child 
Reported - Measures appetite behaviours 
The Child eating behaviour questionnaire: (CEBQ) Ages 5 – 12 – Parent 
reported - Measures appetite behaviour 
The Achenbach Child Behaviour Checklist (CBCL) – Ages 4 – 18 - Parent 
reported - Measures behavioural psychology 
The Food Cravings Inventory (FCI) 5- 16 yrs – Child reported – Measures food 
cravings 
Food intake questionnaire  (FIQ) 5 -1 6 yrs – Child reported  - Measures food 
intake 
Body Mass Index (BMI) – Measures weight. 
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Chapter 2:5 Methods of Data analysis 
Below are the statistical analyse employed for the study: 
Univariate analyses with appetite behaviour as dependent variable: 
-Pearson‘s correlation between PedMIDAS score (measure of migraine 
severity) and CEBQ and DEBQ eating behaviour subscale scores. 
-ANOVA will be utilised, using categories of migraine severity, dependent 
variable are CEBQ score and DEBQ score as above. 
Multivariate analyses with eating behaviour as dependent variable: 
-PedMIDAS, CBCL, BMI, sex, age, as independent variables, with eating 
behaviour scores as dependent. 
-Univariate analysis for the migraine effect with adiposity as the dependent 
variable, as reported in previous studies (chapter 3.2). 
-Pearson‘s correlation between PedMIDAS score (measure of migraine 
severity) and BMI z-score (measure of adiposity). 
Multivariate analysis- a mediation analysis to demonstrate migraine acts through 
eating behaviour to cause effect on adiposity 
-Multivariate analysis using eating behaviours scores and PedMIDAS 
migraine severity scores as independent variables and BMI z-score as 
dependent variable. 
-A descriptive analysis of food cravings and other dietary behaviours. 
- Sample size discussed in chapter 2.2.  
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CHAPTER 3: literature review results: 
Chapter 3.1 Critical analysis of each relevant study: 
To formally critically analyse the previous studies in the relevant area of 
research, the Strengthening of The Reporting of Observational studies in 
Epidemiology (STROBE)(170) tools (refer to Appendix C and D) were 
utilised. Individual tools for each type of study e.g. case control were 
available to apply to the relevant studies. STROBE is being endorsed by a 
growing number of biomedical journals to improve the rigour of published 
work. It was not necessary, in this case, to design more formal inclusion 
criteria, for a systematic review of the literature in order to certify high 
quality studies, because there were so few studies in this area of interest. If a 
larger volume of studies existed in the area, formal inclusion criteria would 
have been adopted. All of the relevant studies in this area have been included 
below. 
Chapter 3.1.1 Study 1: Obesity and migraine: A population study. Bigal ME et 
al(44) 
This study was a population based, cross-sectional study. The methodology 
was a population based telephone interview. There were 30,215 participants 
recruited into the study over a three year time period. The aim of the study 
was to assess the influence of BMI on headache prevalence, frequency, 
severity, disability and associated headache symptoms. The study predicted, 
based on previous work showing that the odds of chronic daily headache 
were five times greater in obese patients (104), that obesity would be 
associated with migraine prevalence and severity. The study gave a 
reasonable biological plausibility, citing the overlap of CGRP and 
inflammatory markers in both pathologies. 
 
The methodology of the study was contacting a large population sample 
using a computer-assisted telephone. Participants were firstly screened for 
eligibility. Eligible consenting participants then agreed to a scheduled 
telephone interview. Large amounts of data were recorded regarding 
participants‘ headaches. This included frequency and severity (using a scale 
 64 
of 1 -1o) of headache and covered all necessary questions for diagnostic 
criteria of migraine in the IHS. Participants were also to self report their 
height and weight so that their BMI could be calculated. Baseline 
demographic data was also assessed. A thorough discussion of the statistical 
methods was given. 
 
Results of the study showed that migraine prevalence did not statistically 
significantly differ in overweight, obese, or morbidly obese categories when 
compared to normal weight patients. This is contrary to this study‘s 
hypothesis. In keeping with the hypothesis, however, high BMI was 
associated with increased headache frequency. In comparison to 4.4% of 
normal weight participants having 10-14 headache days per month, 5.8% of 
overweight (OR 1.3), 13.6% of obese (OR2.9) and 20.7% of morbidly obese 
(OR 5.7) had 10-14 headache days per month. Furthermore, BMI was also a 
predictor of migraine features. Participants with sequentially higher BMI 
reported sequentially greater number of headache features, a predictor of 
severity. 
The crucial findings of this paper highlight that increased BMI was not 
associated with increased migraine prevalence. In keeping with the previous 
longitudinal migraine obesity study by Scher et al(104), however, obesity 
was associated with increased headache frequency. Further findings were 
that BMI was associated with severity of migraine, and a number of migraine 
features, such as photophobia. Because the study was cross sectional, the 
authors did not imply any causality in the migraine obesity relationship.  
 
A number of limitations to this study were highlighted when critically 
appraised using the STROBE tool for cross sectional studies. Firstly, no 
potential confounders were discussed in the methodology of the study. 
Furthermore, there was no discussion of how sample size was arrived at. 
Sources of bias were not identified in the methodology, nor were missing 
data identified in the study. Similarly, numbers of participants at each stage 
of recruitment were not highlighted. 
 
The authors did highlight some other limitations. Firstly, they attributed the 
over representation of females (65%) in the study to phone calls taking place 
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in business hours. Secondly, they highlighted that food triggers were not 
addressed in the survey. The authors suggested that they expected less food 
avoidance in increased BMI groups, but this was not assessed. Equally, 
depression, a co-morbidity of both diseases, was not formally addressed. 
Most importantly, they highlighted that the largest limitation of the study 
was that height and weight were self-reported by participants. They suggest 
that obese participants may have under-reported their weight, and this may 
have reduced the effect size of the study‘s findings. 
 
The findings of this study are important; it is the largest study in this area of 
interest. It strongly augments previous work, underlining the link between 
obesity and the frequency and severity of migraine. Furthermore, it does not 
negate the theory of this thesis; this being a cross sectional study, causality 
can only be postulated, as in all previous studies. It remains plausible, in 
keeping with the hypothesis of this thesis, that migraine could cause poor 
appetite leading to obesity, and this obesity then worsening migraine. 
 
Some of the limitations of this study offer insight into how to structure the 
pilot study design. For example, it will be important to address avoidance of 
food triggers in the cohort of patients. It will be interesting to see if there is a 
consistent trend between patients of different weight. Furthermore, it will be 
interesting to see if there is variation of food avoidance in patients with 
varying appetite behaviour. It is plausible that those with most aberrant 
appetite behaviour scores would avoid food triggers the least. Similarly, this 
study suggests those with highest BMI avoid food triggers least. 
 
Chapter 3.1.2 Study 2: Obesity is a risk factor for transformed migraine but not 
chronic tension-type headache. Bigal et al(100) 
 
This study was a population based cross sectional study. The methodology 
was, again, a telephone based interview. It was a very large population of 
30,215 participants, recruited over a three-year period. The aim was to assess 
the influence of BMI on chronic daily headache and, in particular, its two 
most common subtypes, chronic migraine and chronic tension type headache. 
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The results showed that BMI had a strong influence on chronic migraine 
(OR 2.2 in the obese category), but that BMI influence on chronic tension 
type headache was not significant. It appears from scrutinising this paper 
that this study is a sub section of study one above. The recruitment was at 
the same time period and the number of participants is identical. At no point 
during the published paper do the authors explicitly highlight if this is the 
case. This ambiguity is a limitation of the study. Given that the explanation 
of the methodology is identical in this study as for study one, it is reasonable 
to conclude that both studies are from the same recruitment process. It 
appears that the authors have conducted a sub analysis of the participants 
with chronic daily headache (1,243 participants) from their original large 
population. From this sub group they have correlated the different types of 
chronic daily headache against BMI, to yield the results mentioned above. As 
such, the limitations from study one (above) also applicable to this study. 
Chapter 3.1.3 Study 3: Factors associated with the onset and remission of chronic 
daily headache in a population-based study. Scher et al(104) 
This study was a population based longitudinal case control study. There 
were 1932 participants (1134 cases and 798 controls). The aim of the study 
was to describe factors that predict chronic daily headache ((CDH - defined 
as 15 or greater headaches a month) onset or remission in an adult 
population. The methodology of the study was that patients were put into 
the case category if they were recorded to have 180 headaches or more per 
year and control category if they had between 2 and 102 headaches per year. 
55,255 patients were recruited at baseline into the study. Patients with 103-
179 patients were not included in the study. The authors used a broad 
headache frequency for the control arm, to assess whether baseline headache 
frequency was a risk factor for CDH onset. There were 798 controls and 
1134 cases available for follow up phone interview at 11 months.  Large 
amounts of data were recorded pertaining to the marital status and physical 
attributes of patients at baseline. Of interest to the planned study, the BMI of 
all participants was based on participant self report of height and weight at 
baseline and follow up. 
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The results of the study showed two important findings. Firstly, the 
prevalence of chronic daily headache was associated with obesity (BMI > 30).  
Secondly, the development of CDH was associated with obesity. In other 
words, at baseline interview the population cases of CDH were found to have 
a significant association with obesity. At follow up interview, the incident 
cases of CDH (i.e. increase in headache frequency from 2-104 to >180 in the 
time frame of 11 months) was significantly associated with obesity. 
This study is important for a number of reasons. Firstly, it is the only 
longitudinal data focused on the association between migraine and obesity. 
Secondly, it is an adult based study thus, although one can postulate cause 
and effect of migraine and obesity, causality remains unclear. Essentially, 
causality cannot be determined in participants with established migraine and 
established obesity.  It remains plausible that migraine could have caused 
poor appetite behaviour leading to obesity, which subsequently caused 
migraine transformation, rather than the reverse. The fact that it is in an 
adult population obfuscates the cause and effect of this relationship, again 
highlighting the need for the planned study in a paediatric population. 
Chapter 3.1.4 Study 4: Headaches in Overweight Children and Adolescents Referred 
to a Tertiary-care Centre in Israel. Pinhas-Hamiel et al(106) 
This study was a questionnaire based case control study in a paediatric 
population in Israel. The aim was to ―assess the association between obesity 
and primary headaches in children and adolescents(106)‖. The crucial finding 
of this paper was that obese adolescent female participants had a four times 
greater risk of headache than participants of normal weight. The discussion 
of links between the two diseases is limited. The focus is on co- morbid 
conditions such as hypertension, along with discussion on excessive 
television watching being linked to both conditions. There was no mention 
of neurobiological plausibility throughout the study. Importantly, the study 
is very vague in explaining its methodology and recruitment process and at 
no point explicitly defines the study as case control. Only from scrutinizing 
the paper at length does this become clear. Obese cases were recruited from a 
tertiary endocrine clinic and controls from a general paediatric clinic. Once 
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this is established it becomes clear that they present their results in a very 
unorthodox fashion. To clearly exemplify this a table (table 3) is needed: 
Table 3: Cases and controls in Pinhas-Hamiel et al(106) study: 
 Headache Not Headache 
Overweight/Obese 
(case) 
27 130 
Normal weight 
(Control) 
12 104 
 
The exposure in this study is migraine; overweight and normal weight 
patients (underweight patients were not recruited) were recruited from an 
endocrine and general paediatrics clinic respectively, to assess whether or 
not they have headache. Once the cohort of 39 patients migraine patients 
were found, however, they were re-examined to address the patient‘s weight. 
Thus the results are presented as if weight (i.e. obesity) is the exposure for 
headache, when in fact the reverse is the case. This could possibly be why the 
design of the study (case control) is obfuscated somewhat. Furthermore, their 
pre-specified hypothesis is equally vague. There is no direct discussion of 
primary and secondary outcomes. 
A strong feature of the study is that it gives a description of the variables 
that would be considered in analysis. It gives an in depth discussion of the 
statistical methods employed and discusses the logic behind the power 
calculation sample size of 120 children in each group. This calculation 
yielded an 80% power to detect a two-fold difference between children of 
normal weight and overweight children. The authors even explicitly 
highlight the caveat that the power calculation is based on the assumption 
that the prevalence of headaches in children is 15%. They also highlight that 
the interpretation of results should be taken with suitable caution, 
highlighting limiting factors such as the study being underpowered, and 
several co-variates, such as exercise patterns not being assessed. 
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There were, however, weaknesses in the results component of the study: 
numbers of individuals at each stage were not reported e.g. potentially 
eligible, reasons for non-participation were not cited and characteristics of 
participants were not comprehensively state.  
This study highlights a number of interesting issues. The key finding is that 
it female, but not male, overweight participants were at increased risk of 
headaches. The authors offer no explanation of why there is discrepancy 
between the sexes.  It is the only case control study focusing on headache 
and obesity in children. It has only been published in the time that this 
MPhil has been conducted, highlighting the timeliness of the proposed study. 
The study itself highlights that females have a four times greater risk of 
headache. Although this result is persuasive, it must be regarded with 
caution, considering the unconventional presentation of methodology and 
results discussed above.  
The study also includes all types of primary headache, including tension type 
headache. As mentioned in the neuropeptides section (section 1.4), migraine 
and specifically migraine with aura, is arguably the most biological headache; 
that being that there is a very complex pathophysiology underlying the 
disease. In contrast, for example, to medication overuse headache, which has 
a clear straightforward reversible stimulus. Migraine is also considered to 
give the greatest morbidity to its sufferers. Thus, in fitting with this thesis, it 
is unsurprising that the association of any primary headache with obesity is 
relatively small (in males there was no difference in headache prevalence 
between the weight groups). Hence the planned study will focus on migraine 
severity and appetite behaviour (as a predictor of adiposity) aiming to offer 
an insight as to whether a severe, complex biological headache, i.e. migraine 
will have stronger association with poor appetite behaviour and subsequent 
obesity than general primary headaches was found to in Pinhas-Hamiel‘s 
study.  Pinhas Hamiel‘s study pontificated cause and effect between 
paediatric headache and obesity. As aforementioned, however, no causality 
can be determined in a study where both migraine and obesity are already 
established. Thus, the planned study is no less valid; rather it highlights the 
need for cause and effect to be established. 
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3.1.5 Study 5: Obesity in the paediatric headache population: A multi centre study. 
Hershey et al (see Appendix E)(107) 
This study was a retrospective case series analysis of 913 consecutive 
migraine patients in seven specialist headache paediatric centres. The 
objective of the study was three-fold: Firstly, to assess the prevalence of 
obesity in migraine patients; Secondly, to examine the relationship between 
obesity and frequency and disability of headache and, thirdly, to examine the 
effect of weight change on headache frequency and disability. The authors 
hypothesised that prevalence and frequency of migraine would be increased 
in obese patients, based on the previous findings by Bigal et al(44). 
The methodology of the study is obfuscated somewhat in the publication. It 
initially appears as if patients were recruited prospectively and administered 
the pedMIDAS tool (as a measure of their headache disability), with their 
height and weight being measured simultaneously. By further scrutiny it 
becomes clear that this is a very simple study design. It is, in essence, a 
retrospective case-only analysis of patients who have being routinely 
administered pedMIDAS at clinics and had their height and weight 
measured. 
The results showed that obesity levels were high, with 34.1% of participants 
categorized as either at risk of overweight (85-94th BMI percentile) or 
overweight (95th BMI percentile or above), but this did not statistically 
deviate from estimated U.S prevalence (107) of obesity in the paediatric 
population. The study did show that BMI percentile was significantly 
correlated with headache frequency and disability (measured by the 
pedMIDAS); however, the association of BMI percentile with headache 
frequency (r=0.10, P=0.03) and disability (r=0.10, P=0.2) were only modest. 
One reason for this could be the incorporation of all primary headache types 
into the study. Previous associations between headache and obesity have 
been specifically between migraine and obesity(109); it has been shown that 
chronic daily headache and obesity are linked(100), and that increased BMI 
increased migraine frequency(44). The authors accepted that one cannot 
derive causality in the relationship between the two pathologies due to the 
nature of this study. The authors did cite the commonly known 
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neurobiological overlap to highlight the association. The authors highlight 
the need for further study in this area to establish the underlying mechanism 
that relates the two diseases. This study again underlines the need for the 
proposed study, to see if appetite behaviour has a role in the intermediary 
step between migraine and obesity. Hershey et al have certainly highlighted 
that the obesity and migraine relationship exists in the paediatric population 
as well as the adult population; however, they shed no light on the causality 
of the relationship between the two. Obese patients that have headache may 
have previously been normal weight and still had headaches prior to the 
onset of their obesity; this cannot be elucidated from their study due to the 
methods employed in the work. 
3.1.6 Study 6: Obesity and paediatric migraine. Kinik et al (108) 
This study was a retrospective case series of 124 migraine patients in a 
paediatric neurology clinic in Turkey. It aimed to assess the influence of BMI 
on migraine severity and frequency. Secondarily it assessed the influence of 
BMI on associated migraine symptoms. 
The methodology of this study was straightforward; 124 patients‘ notes were 
accessed over a six year period and the following data were collected: 
characteristics of headache frequency over the last three months, severity 
based on a verbal report of a 1-10 scale and associated symptoms such as 
photophobia and phonophobia. Their method of weight measures was 
original, utilizing relative BMI ((relBMI) = BMI X 100/50th percentile BMI 
for patient‘s age and sex). This calculation is the individual‘s BMI divided by 
a standard BMI for their sex and age(210). The advantages of this are that it 
can help standardise BMI across age and sex and it allows you to follow 
tracking and changes in BMI as more accurately(210). Using this method, 
normal weight was a score of <110, overweight 110 -120, obese >120. 
The study showed a number of interesting findings. Obesity prevalence of 
this cohort of migraineurs was 17.7%; significantly higher than the latest 
obesity figures for this age grouping in Turkey (6.1%)(211). In keeping with 
the large adult population study by Bigal et al(44), there was a statistically 
significant correlation between obesity and increased migraine frequency 
(headache frequency per month - obese 5.3%, overweight 4.4%, normal 
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weight 3.8% - P=0.018). In contrast to Bigal et al(44), however, they did not 
find a significant association between relBMI and migraine severity or 
relBMI and associated symptoms. 
The discussion of the findings in this study is poor. Firstly, the authors offer 
no consideration of how to reduce bias, nor do they offer any limitations of 
their study. They do not highlight any missing data; furthermore, they give 
no indication of the recruitment process, for example, whether patients were 
consecutively recruited, which leaves the reader to assume this was not the 
case. There is no interpretative explanation for the disparity between their 
study and the Bigal et al(44) study, which showed a statistically significant 
association between increased weight with increase in severity and associated 
symptoms. The majority of the discussion merely highlights the findings of 
other studies rather than focusing on their own. 
The strength of the study is that this is the first paediatric population where 
specifically migraine (as opposed to all primary headaches) severity and 
frequency have been correlated with predictors of weight. Thus it is an 
important finding that, as in the adult population, obesity was associated 
with increased migraine frequency. 
Another strength of the study is that it highlights the importance of orexin A 
and B in the overlapping neurobiology of migraine and obesity. The majority 
of other studies overlook these important neuropeptides. 
Overall, this study has a basic methodology and the key finding is that once 
more obesity was associated with migraine frequency, but this time this has 
been found in the paediatric population. It did not show an association with 
migraine severity and obesity. Once again causality cannot be derived from 
these findings, this being a cross-sectional retrospective case series, however, 
it is clear that this study has a very similar hypothesis to the large population 
study by Bigal et al(44), and is looking at the relationship from the 
perspective of obesity worsening migraine. 
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Table 4: Summary of studies addressing the relationship between migraine and 
obesity hitherto 
Authors Sample  
size  
Study design Method Results 
Scher et 
al 
1932 
 
 
 
Prospective 
longitudinal 
case–control 
design. 
 
 
Two phone interviews at 0 and 
12 
Months – address factors that 
influence onset or remission of 
CDH. 
Odds of CDH were 
five times 
Higher in obese and 
3x higher in 
overweight 
Compared to normal 
weight. 
Bigal et 
al 
30,215 
 
Cross 
sectional, 
population 
based 
telephone 
survey. 
Population-based, telephone 
interview – to assess influence of 
BMI on headache severity and 
frequency. 
Odds of having very 
frequent headache 
2.9 in obese and 5.7 
in severely obese 
compared to normal 
weight. 
Bigal et 
al 
30,215 Cross sectional 
population 
based 
telephone 
survey. 
Population-based, cross-sectional 
survey - assessing the 
relationship between obesity and 
several episodic headaches. 
Obesity was 
strongly associated 
with increased 
frequency of 
headache. 
Pinhas   
–Hamiel 
et al 
178 Case – control 
questionnaire 
based study. 
Questionnaire and 
anthropometric measurements – 
to assess prevalence of headache 
in obese and overweight. 
Female headache 
patients had a four 
times greater risk of 
obesity. 
 
Hershey 
et al 
913 Retrospective 
case –series. 
pedMIDAS and anthropometric 
measurements - to assess effect of 
obesity on migraine prevalence, 
frequency and severity. 
Obesity associated 
with headache 
frequency,  but not 
prevalence. 
Kinik et 
al 
124 Retrospective 
case-series. 
Migraine severity scale (1-10), 
Headache frequency and relative 
BMI (relBMI) was collected to 
assess relationship of weight on 
headache severity and frequency. 
Obesity associated 
with increased 
migraine prevalence 
and frequency, but 
not severity. 
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Table 4 is a summary of all the studies highlighted in the formal literature 
search studies that focused on the migraine and obesity relationship. The 
first three are adult studies whilst the latter three are paediatric studies.  
Figure 7: Reviewing the direction of causality in migraine, appetite behaviour and 
obesity
 
From the hypothesis generation and critical analysis sections of this thesis, it 
is clear that in work hitherto that there is a relationship between migraine 
and obesity. From the formal literature review, it is clear that hitherto no 
work has established the cause and effect of the relationship between 
migraine and obesity. This is highlighted in this diagram (figure 7) by the 
large blue and pink arrows. The direction of effect remains elusive. 
Furthermore, the appetite behaviour section should highlight 
comprehensively the evolving link between appetite behaviour and obesity. 
The blue two-way arrow represents this. This pilot study‘s hypothesis is that 
due to the underlying neurobiology, migraine causes aberrant appetite 
behaviours, which may lead to increased adiposity and subsequent onset of 
obesity. This is indicated by the large pink arrow, and is yet to be formally 
studied. To firmly test such an association, a large longitudinal study is 
necessary. Thus, this pilot study aims to correlate whether increased 
migraine severity is associated with increasingly aberrant appetite 
behaviours (represented by the two way pink arrow). This will be a crucial 
stepping-stone to the overall hypothesis. 
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 Chapter 4: Results: 
4:1 Primary outcome results: 
Figure 8 below highlights the response rate in the preliminary recruitment of 
the study. Only 56% of potential participants fully completed the 
psychometric tools. 
Figure 8: Response rate 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Basic 
Potential participants 
-16 
Participants that 
agreed to take 
part in study - 14 
Participants   that 
refused to take 
part in study - 2 
 
Error in 
recruitment 
process– 
participant didn’t 
fit inclusions 
criteria - 1 
Participant 
withdrew consent 
for study - 1 
Patients  that 
completed 
recruitment into 
study – 12 
 
 
Participants that 
did not complete 
all relevant 
psychometric 
tools - 3 
Participants 
that 
completed all 
relevant 
psychometric 
tools - 9 
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demographics of participant population: 
Category Classification N % 
Sex M 3 30 
 F 7 70 
Race White British 10 100 
 Other 0 0 
Age 5-12 4 40 
 13-16 6 60 
BMI Underweight 0 0 
 Normal weight* 9 90 
 Overweight* 1 10 
 Obese* 0 0 
Diagnosis Migraine 10 100 
 Not migraine 
(control) 
0 0 
 
* N.B based on BMI z-scores. 
Table 5 is a simple summary of the demographics of the participant 
population. It is clear to see the very small sample size recruited. All 
participants were white British and the vast majority were normal weight. 
There were more females recruited into the study. All participants were 
migraine sufferers.  
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Table 6: Dutch eating behaviour questionnaire scores: 
 
Population 
N=9 Emotional 
eating 
M(S.D) 
External 
eating 
M(S.D) 
Restraint 
eating 
M(S.D) 
Both sexes N=9 1.62 (0.57) 2.23(0.61) 1.58(0.75) 
F N=7 1.66 (0.62) 2.32(0.41) 1.66(0.83) 
M N=2 1.48(0.46) 1.99(1.26) 1.3(0.42) 
Age 9-12 N=3 1.23(0.28) 1.93(0.85) 1.13(0.23) 
Age 13-16 N=6 1.82(0.59) 2.4(0.41) 1.75(0.78) 
 
4:1:2 Description of Dutch Eating Behaviour Questionnaire findings 
Table 6 shows the mean scores of the three categories of appetite behaviour 
addressed by the DEBQ in the cohort studied. The average male 
migraineurs‘ emotional eating score was 1.48, which is within the average 
range (1.24-2.84)(132). The average female migraineur score of 1.66 is within 
the average range (1.31-1.68)(132). The average range is defined by the 
DEBQ user manual, which categorises the three separate strands of appetite 
behaviour into below average, average and above average aberrant 
behaviours based on large population norms.  The average male migraineurs‘ 
external eating score was 1.99, which is in the ‗below average‘ category 
(<2.18)(132). Similarly, female migraineurs‘ score of 2.32 was in the ‗below 
average‘ category (1.89-2.49). The average male migraineurs‘ restraint eating 
score of 1.3, within the average category (0.92-2.12)(132), whilst the average 
female migraineurs‘ score of 1.66, was in the ‗below average‘ category (1.30-
1.84)(132). There were no data in the Dutch eating behaviour manual to 
formally compare age ranges with comparable age categories, It can be 
noted, however, that between age groups in this migraine population, 
external, emotional and restraint eating scores were consistently higher in 
the elder age range. 
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Due to the unexpectedly small sample size yielded in the study, it is futile to 
conduct statistical correlations between the DEBQ and pedMIDAS, nor the 
CEBQ and pedMIDAS, because it would be erroneous and unscientific to 
draw any meaningful conclusions from such a small sample size.  
 
Table 7: Childrens Eating Behaviour Questionnaire scores: 
 Overall M F Age 5-12 
Age 12-
16 
N 10 3 7 4 6 
Satiety 
Responsiveness 2.9(0.77) 3.1(1.47) 2.83(0.37) 3.35(0.75) 2.6(0.69) 
Slowness in 
Eating 2(0.73) 2.33(0.80) 2.1(0.87) 2.25(1.06) 1.84(0.44) 
Food Fussiness 3.61(0.94) 3.6(1.51) 3.62(0.76) 3.67(1.30) 3.57(0.76) 
Food 
Responsiveness 2.18(1) 1.73(0.64) 2.37(1.1) 1.75(0.57) 2.47(1.2) 
Enjoyment of 
Food 3.36(0.88) 3.1(1.76) 3.5(1.02) 
2.94 
(1.18) 3.5(1.1) 
Desire to 
Drink 2.57(1.22) 2.33(1.53) 2.67(1.18) 
1.58  
(0.69) 3.23(1.04) 
Emotional 
Undereating 1.88(1.04) 1.5(0.866) 2.04(1.12) 1.75(0.87) 1.89(1.32) 
Emotional 
Overeating 1.55(0.51) 1.25(0.25) 
1.68 
(0.55) 1.63(0.63) 1.5(0.47) 
 
4:1:3 Description of CEBQ scores 
Table 7 shows the mean scores of the eight categories of appetite behaviour 
addressed by the CEBQ in the cohort studied. Migraineur scores from this 
study were compared to normal population CEBQ score averages from the 
author‘s of the CEBQ original validation of tool study(198). Overall 
migraineurs have a lower than average satiety responsiveness of 2.9 (mean 
3.1)(139). Females have a lower satiety responsiveness than average 2.83 
(mean 3.1)(139) whilst males have an exactly average score 3.1 (mean 3.1). 
The average scores are the normal scores recorded by the authors of the tool 
when validating the tool(139).  
Both males and females independently had a lower slowness in eating score 
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than average, with 2.33 (average 3.1) and 2.1 (average 3.2) respectively(139). 
Elder migraineurs showed more pronounced fast eating rates (1.84) 
compared to younger migraineurs (2.25)(139).  
The overall migraineurs‘ score for slowness in eating was below average 2 
(average 3.15)(139) (139). Food fussiness was above average in the 
population, being 3.61 (average 3)(139). Both migraine girls and boys 
independently had a higher satiety score, being 3.62 (average 2.9) and 3.6 
(average 3.1) respectively(139).  
Food responsiveness of the overall population was just below average, being 
2.18 (average 2.25)(139), however, there was a difference between the sexes. 
Female migraineur scores were just above average 2.37 (average 2.3). Males 
migraineur scores of being 1.73 were below average (average 2.2)(139). 
Enjoyment of food scores for the whole population were below average at 
3.36 (average 3.6)(139). Independently, male migraineurs‘ scores were 
substantially below average at 3.1 (average 3.6)(139), whilst female 
migraineur scores were just below average at 3.5 (average 3.6)(139). 
Desire to drink scores for the population were below average at 2.57 
(average 2.9) (139). Females migraine scores were independently below 
average, being 2.67 (average 2.9), as were male migraine scores, being 2.33 
(average 2.3)(139).  
The overall scores in this population for emotional under eating were lower 
than average, being 1.8 (average 3.05)(139). Male migraineurs scored 
substantially under average, scoring 1.5(average 3.1). Similarly, female 
migraineurs scored under average scoring 2.0 (average 3.0)(139).  
The overall score for the population for overeating was 1.5, which is less 
than the average mean (1.8). Both male migrainuers, scoring 1.2 (average1.8), 
and females migraineurs, scoring 1.6 (average 1.8), achieved under average 
scores.  
 
 
 80 
Table 8: Paediatric Migraine Disability Assessment Questionnaire scores: 
Patient pedMIDAS 
score 
Severity Frequency Severity 
1 3 0 8 4 
2 0 0 4 5 
3 11 1 2 8 
4 21 1 12 10 
5 120 3 30 9 
6 34 2 8 6 
7 5 0 2 10 
8 12 1 3 9 
9 0 0 3 4 
10 43 2 30 9 
11 53 3 52 9 
Mean 27.46 1 (mild) 14 7.5 
 
4:1:4 Description of pedMIDAS results 
Table 8 shows the individual sub domain scores for each participant who 
completed the pedMIDAS questionnaire. The mean pedMIDAS score in this 
population, 27.46, is lower than those given by the authors of the tool, which 
were 44.3(11). The mean pedMIDAS severity from these results therefore, is 
classified as mild, in contrast to the authors‘ mean score, which equates to a 
moderate pedMIDAS severity(11). The mean frequency of headache in this 
group was 14, higher than the mean given by the authors of the tool 9.5(11). 
Furthermore, the mean self reported migraine severity by this group was 7.5, 
again higher than the pedMIDAS authors‘ mean of 5.6(11). 
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4:2: Secondary outcome results: 
Table 9: Food Cravings Inventory scores: 
Population Total 
group 
M F Age 5 -
12 
Age 13-16 
N 12 4 8 3 9 
Total FCI 2.55(0.31) 2.48(0.18) 2.74(0.58) 2.56(0.44) 2.5(0.3) 
FCI – high 
fat foods 
2.08(0.62) 
 
2.25(0.13) 
 
1.93(0.70) 
 
2.10(0.26) 
 
2.07(0.71) 
 
FCI - 
sweets 
2.67(0.76) 
 
3.04(0.86) 
 
 
2.48(0.64) 
 
2.59(0.50) 
 
 
2.71(0.88) 
 
FCI-
carbohydra
tes 
2.75(0.76) 
3.25(0.42) 
 
2.50(0.62) 2.88(0.46) 2.69(0.76) 
FCI –Fast 
foods 
2.71(0.74) 
 
2.75(1.19) 
 
2.69(0.50) 
 
 
2.81(0.55) 
 
2.5(0.78) 
 
 
4:2:1 Description of FCI scores 
Table 9 shows the mean scores of the four food categories addressed by the 
FCI in the cohort studied. The overall mean scores of cravings for male and 
female migraineurs were above population normal comparisons. Male scores 
were 2.48 (population normal average 2.00), whilst female scores were 2.74 
(population normal average 2.07)(126). 
The results of food cravings for high fat foods show that male migraineur 
scores were substantially above average at 2.25 (average 2.00) whilst female 
migraineur scores were actually below population normal average at 1.93   
(average 2.07)(126). No research has assessed mean food cravings inventory 
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scores in the paediatric population; there are no comparisons, therefore, that 
can be drawn from these findings. 
Food cravings scores for sweets were higher in both males and female 
migraineurs than in comparison groups. Males scored 2.48 whilst females 
scored 3.04, both higher than comparison means of 1.92 and 2.17 respectively 
(126).  
Cravings for carbohydrates were higher than average in both sexes. Male 
migraineur scores were 2.5, higher than the average of 2.13. Female 
migraineur scores were 3.25, much higher than controls of 2.31(126).  
Cravings for fast foods were higher than average in both sexes of 
migraineurs. Male migraineur scores were 2.69 (average 1.97), whilst female 
migraineurs scores were 2.75 (average 1.85)(126). 
Table 10: Child Behaviour Check List Scores: 
Population Total 
group 
M F 
N 11 3 8 
Internalising 7.91(3.83) 6.67(2.89) 8.38(4.2) 
Externalising 14.9(7.46) 
16.67(9.29) 
15.5(8.6) 
Withdrawn 
behaviour 
2.91(2.21) 2.67(1.15) 3(2.56) 
Somatic 
behaviour 
1.64(1.2) 1.67(0.57) 
1.63(1.41) 
Anxious 
behaviour 
3.36(2.5) 2.33(3.2) 3.75(2.3) 
Delinquent 2(2) 2.67(2.3) 1.75(2.1) 
Aggressive 14.5(7.9) 15.5(8.6) 13.3(4) 
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4:2:2 Description of Child Behaviour checklist scores 
Table 10 highlights the average scores of the individual abnormal 
psychological traits addressed by the CBCL in the cohort studied. Male 
migraineur internalizing scores of 6.67 were below the average normal 
population scores of 7.5. Female migraineur internalizing scores, of 8.38, 
were above average for the normal population 8.1(212).  
Male migraineur externalizing scores of 16.3 were higher than normal 
population comparisons of 11.9. Similarly, female migraineur externalizing 
scores of 15.5 were higher than normal population comparisons of 9.5. 
Male migraineur withdrawal scores of 2.67 are higher than normal 
population comparisons of 1.9. Similarly, female migraineur withdrawal 
scores of 3 are higher than normal population comparisons of 2.  
Male migraineur somatic scores of 1.67 are higher than male normal 
population comparisons of 0.8. Similarly, female migraineur somatic scores of 
1.63 are higher than female normal population scores of 1.  
Male migraineur anxiety scores were 2.33, lower than the male normal 
population scores of 4.9. Female migraineur anxiety scores were 3.7, lower 
than the female normal population scores of 5.2.  
Male migraineur delinquent scores of 2.67 were marginally higher than 
normal population scores of 2.5. Female migraineur delinquent scores of 1.75 
were marginally lower than normal population scores of 1.9.  
Male migraineur aggression average scores of 15.5 are higher than normal 
population scores of 9.6. Similarly, female migraineur aggression average 
scores of 13.3 are higher than normal population scores of 7.6.  
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Table 11: Food Intake Questionnaire Scores: 
Marker 
food 
NUMBER 
OF 
FOODS 
IN 
GROUP 
Overall 
(10) 
 
 
Boys (3) Girls (7) 
Sugary 13 2.2(1.99) 1(1) 2.71(2.14) 
Fatty 10 1.9(1.29) 2(1) 1.86(1.46) 
Fibre 10 0.6(0.52) 0.66(0.58) 
 
0.57(0.53) 
Snacks 10 1.7(1.3) 1.33(1.53) 1.6(1.27) 
Altered 
fats 
5 0.9(0.1) 1(1) 0.86(1.21) 
Low 
sugar 
3 0.7(0.82) 1(1) 0.57(0.79) 
Negative 
food 
marker 
21 4.2 (2.34) 4(2.65) 4.71(2.21) 
Positive 
food 
marker 
21 2(1.75) 2(1) 2(2) 
 
4:2:3 Description of FIQ Scores 
Table 11 shows the mean scores of the different food markers addressed by 
the FIQ in the cohort studied. Male migraineur mean scores of sugary food 
intake were 1; substantially lower than normal population scores of 
6.29(204).  Similarly, mean female migraineur scores of sugary food intake 
were 2.7; substantially lower than normal population scores of 5.44(204).  
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Male migraineur mean scores of fatty food intake were 2; lower than mean 
normal population scores of 3.69(204). Similarly, female migraineur mean 
scores of fatty food intake were 1.86, lower than mean normal population 
scores of 3.24.  
Male migraineur mean scores of fibre food intake were 0.66; lower than mean 
normal population scores of 2.54(204). Similarly, female migraineur mean 
scores of fibre food intake were 0.57; lower than mean normal population 
scores of 2.27(204).  
Male migraineur mean scores of snack food intake were 1.33; lower than 
mean population scores of 5.86(204). Similarly, female migraineur mean 
scores of 1.6 were lower than normal population mean scores of 5.33(204).  
Male migraineur mean scores of altered fats intake were 1.00; lower than 
mean population scores of 1.45(204) . Similarly, female migraineur mean 
scores of 0.86 were lower than normal population mean scores of 1.24. This 
could suggest that, in both sexes of the migraine population, intake of altered 
fat food was lower than their normal population contemporaries. 
Male migraineur mean scores of low sugar food intake was 1.00; slightly 
higher than the mean population score of 0.9(204). Female migraineur mean 
scores of 0.57 were lower than the normal population mean of 1.8(204).  
Male mean scores of negative food markers were 4; substantially less than 
the normal population mean of 10.02(204). Similarly, female mean scores of 
negative food markers were 4.71; substantially less than normal population 
means of 8.89.  
Male migraineur mean scores of positive food markers were 2; less than the 
normal population mean of 5.73(204). Female migraineur mean scores of 
positive food markers were 2; less than in the normal population mean of 
4.93(204).  
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Chapter 5: qualitative results of study: 
5:1 Discourse on use of the psychometric tools: 
A crucial finding from conducting the preliminary recruitment of this study 
has been assessing the utility of the different psychometric tools and the 
validity of the results they produce. There have been a number of issues in 
the use of these tools and it is important that these are reflected upon, 
particularly as some of these tools are widely used, without it being clear 
how extensively they have been validated. The following chapter will reflect 
upon the issues of each tool in turn. 
5:1:1 PedMIDAS 
The authors of this tool validated the tool themselves(11), but no other work 
has analysed its suitability as a tool to measure paediatric migraine disability. 
Question 1 asked, ―How many full days of school were missed in the last 
three months due to headaches?‖ In some cases, participants firstly had to 
seek clarification of the question being asked; therefore, it could be argued 
that the question is not clear. Furthermore, the researcher‘s explanation is 
based on his interpretation of the question, which is not infallible. Moreover, 
the researcher has to paraphrase the question and, in essence, is not asking 
the exact question shown on the questionnaire. Additionally, some 
participants admitted to simply being unable to accurately remember the 
exact number of days missed, so this question is open to recall bias. Often, 
participants would try to recall the full days missed in the previous month 
due to headache and merely multiply that number by three. This method is 
inaccurate in a pathology that waxes and wanes to the extent that migraine 
does. It is clear to see that there are issues of clarity and recall pertaining to 
the first question. 
Question two asked ―How many partial days were missed in the last three 
months due to headache?‖ As with the first question some participants 
needed clarification of this question. Again the researcher had to clarify by 
paraphrasing or giving an example e.g. ―imagine your headache is so severe 
you can‘t get out of bed in the morning and therefore go to school late‖ or 
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―you get a headache that is so painful in school you have to go home early‖. 
This, again, is the researcher‘s interpretation of the question. Another issue 
with two participants was that they had such severe headaches that they 
attended the medical sick room at school for a number of hours but then 
returned to the classroom. In the register, they will show as being in 
attendance at school but certainly were not in attendance at class. This 
ambiguity allows each researcher to interpret this individually and score 
accordingly; therefore, question reliability may be poor. 
 Question 3 asked ―How many days in the last three months did you function 
at less than half your ability in school because of a headache?‖ Most children 
found it very hard to determine exactly if they were functioning at less than 
half their ability. Young children, i.e. 6 year olds, found this impossible to 
answer, whereas an adolescent found it easier to answer the question. Almost 
invariably participants knew when they felt unwell and remained at school, 
and remembered that they could not do work, but could not quantify, in 
certain incidences, if they were functioning at less than 50% of their ability. 
In this researcher‘s experience it seemed that any incidence in which they felt 
even slightly unwell at school was counted as working at less than half their 
function, which in all probability is likely to be an overestimation. 
Question four asked ―How many days were you not able to do things at home 
(i.e. chores, homework etc) due to a headache?‖ This question posed 
particularly difficult problems. The majority of participants felt they did not 
do regular chores or homework so could not answer the question. The 
researcher offered other alternatives such as reading, playing computer 
games, or social networking. Participants felt they could relate better to 
these examples and offered a number of days on which they were unable to 
participate in these activities. It is unclear from the questionnaire, however, 
whether such substitutions of activity are allowed, or whether these 
jeopardise the validity of such a score. This is a limitation of the question. 
Question five asked ―How many days did you not participate in other 
activities due to a headache?‖ The response from participants was very good. 
The vast majority of participants felt they could clearly remember events 
which they had been unable to participate in, however, because they were 
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required to recall events from over three months ago it is still vulnerable to 
recall bias. 
Question six asked ―How many days did you participate in these activities, 
but function at less than half your ability?‖ Again the response to this 
question was positive from the majority of participants, because participants 
could remember the disappointment of not being able to enjoy the event in 
which they were taking part. Once more there is limitation of recall bias over 
the last three months. 
It is clear to see that there are some issues when using the pedMIDAS to 
assess headache disability, which is somewhat surprising discovery given 
that it is used widely for this purpose, for example it is currently being used 
in a national migraine treatment RCT (which is pharmaceutically sponsored) 
in the U.K(47). Ideally the questionnaire should be validated objectively (i.e. 
by scorers who are not the authors of the tool) again, for there are issues, 
particularly the wording of questions, which require revision to improve its 
usability and reliability. 
5:1:3 Dutch Eating Behaviour Questionnaire: 
The Dutch eating behaviour questionnaire has been validated a number of 
times and is a widely used tool for assessing appetite behaviour of children  
age nine to sixteen. It is a thirty three-item questionnaire. The rating score 
is: never; rarely; sometimes; often; very often. Participants understood the 
vast majority of questions and they responded appropriately, however, a few 
questions needed clarification. Question 3 asked ― Do you have a desire to eat 
when you have nothing to do?‖ Many of participants asked whether ―having 
nothing to do‖ meant when they were bored? The researcher assumed this 
was the meaning of the question and responded in the affirmative to this 
question, but this is open to interpretation. It may be better for the question 
to ask, ―Do you have the desire to eat when you are bored?‖ 
Question 9 asked ―If you see or smell something delicious, do you have a 
desire to eat it?‖ A large number of participants asked whether the question 
implied immediate consumption or consumption in the near future e.g. within 
an hour? This author did not know the correct answer to this question and 
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assumed that the question in the tool implied immediate consumption. Most 
participants felt that provided it was a certainty that they would not lose the 
opportunity to eat the treat unless they ate it immediately, they could refrain 
from eating for an hour or two if they knew it was being served soon.  
Question 9 needed to be more specific, because if it meant eating immediately 
or not at all, the results might be considerably different. 
The other questions were answered without issue, highlighting that the 
DEBQ is a very useable questionnaire in this cohort of patients. One issue, as 
with any utilization of a Likert scale, is that participants tried to answer the 
questions as if the options were ‗yes or ‗no‘, giving no consideration to 
degrees of scaling. Even with continual reminder of the true options they 
reverted back to ‗yes‘ or  ‗no‘ and, it is possible that participants use the 
extreme ends of the scale as proxy for affirmative or negative responses. This 
could result in invalid polarised results i.e. taking option one ‗never‘ to mean 
‗no‘ and option 5 ‗very often‘ to mean ‗yes.‘ 
5:1:4 Child eating behaviour questionnaire: 
This questionnaire consists of 35-items. The rating score is never (1), rarely 
(2), sometimes (3), often (4), always (5). This questionnaire is very well 
designed. It is a parent proxy report tool of a child‘s eating. Testament to its 
robust design is the fact that no participants‘ parents had major issues in 
answering the questions. The only question that caused particular issue was 
question 28, which focuses on food reward. Parents are asked to agree or 
disagree with the statement ―Even if my child is full up s/he finds room to 
eat her/his favourite food‖. This caused confusion to a number of 
participants‘ parents. They were unsure whether the food that had made 
their children full up was also their favourite food or an alternative less 
pleasurable food. This is important because parents felt that if the food their 
children had just consumed was their favourite food, e.g. cake, they would be 
less inclined to find room for more of it, but if it were a food such as a 
savoury meal such as roast dinner, that had just been consumed, they would 
be far more likely to make room for their favourite food. This question needs 
clarifying by the authors. It was assumed that it inferred the latter scenario 
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and scored accordingly. The ambiguity of this question is a minor limitation 
of this questionnaire. 
A particular strength of the CEBQ design is that a number of the questions 
are ‗reverse scored‘ i.e. the strongest agreement to a question results in the 
lowest score. The importance of reverse scoring is crucial to this 
questionnaire; it forces the participant to give due consideration to the 
question, and discourages response acquiescence. In this researcher‘s 
experience, the participants were seen to give greater consideration to 
questions asked and the answers given than they might do with other 
psychometric measures. 
5:1:5 Food intake questionnaire: 
This questionnaire is an epidemiological tool that records whether certain 
foods have been eaten on the previous day. It has been used extensively for 
this purpose; one particular study has previously assessed eating habits of 
40,000 children in Liverpool(206). This questionnaire had the best usability 
in preliminary data collection from this study. The questions are very 
straightforward and easy for the participants to interpret e.g. ―Yesterday, did 
you have anything at all to eat or drink before leaving home to come to 
school?‖ The responses required were affirmative or negative, rather than the 
graded Likert scale. Furthermore, the questions were easy to ask and answer, 
so the questionnaire took very little time. This is an important feature of the 
tool because if the questionnaire is lengthy participants become inattentive 
and the reliability of their answers may come into question. This 
questionnaire suitably captured a general description of food intake in 
paediatric migraineurs, however, there were still a few minor issues, one of 
which was recall bias, but it should be remembered this plagues all memory-
based questionnaire. A further issue was that if patients were recruited on a 
Monday or on a half term holiday, some of the questions were not applicable 
to the previous day e.g. ‗did you eat a school lunch (yesterday)?‘ The 
participant was forced to think back to the last day at school, thereby 
introducing greater recall bias. If the day of recruitment was at the tail end of 
a weeklong holiday recall could be a big limitation. Systematic bias occurred 
when parents would contradict the child‘s answer. It is unclear in such 
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circumstances whether the parent is over reporting positive markers of food 
or whether there has been a genuine lapse of memory on the part of the child. 
This finding is probably idiosyncratic, because in previous studies the child 
completed the FIQ in the absence of their parents/carers. Furthermore, this 
researcher asked participants the questions verbally for sake of expediency. 
Whether this had effect on results is unclear. The participant usually 
anonymously answers the FIQ in written format and this may be a reason 
why there is such underreporting. This of course questions the validity of the 
tool in this study, it being used in such a contrasting way from the authors of 
the tool.  Another limitation of the tool is that older children may have 
underreported negative foodstuffs, being aware what constitutes a healthy 
diet. This is therefore a potentially social desirability bias of the tool. Overall, 
this questionnaire was the most useable, capturing food intake in this 
paediatric migraineurs, but a few limitations still existed. 
5:1:6 Food cravings inventory 
This questionnaire is a 28-item questionnaire to assess what types of food 
migraine patients generally crave i.e. their trait food cravings. Participants 
had to rate to what extent they craved certain food on a Likert scale. Options 
were: ‗never‘, ‗rarely‘, ‗sometimes‘, ‗often‘ and ‗always‘. This questionnaire 
was easy to use. Participants responded well to the options, with no 
confusion, or the need for clarification, however the questionnaire had to be 
altered somewhat for our purposes. At the beginning of the questionnaire a 
definition of cravings was given as ―an irresistible urge to consume a specific 
food(200)‖ Although the researcher quoted this definition, because the study 
was interested in trait food cravings, not state cravings (which have already 
been informally looked at(151)) a caveat was added, that participants should 
apply this to everyday living, not specifically around the time of their 
headaches. 
Alterations to a few of the foodstuffs had to be made. Cinnamon rolls were 
changed to swiss rolls, corn bread to crackers, and chips to crisps. This was 
not clarified with the authors of the tool and as such is a limitation of the 
study. However, this was a necessary change to avoid confusion in this 
setting.  
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There were no other issues with this questionnaire and it was very useful at 
elucidating food cravings in this cohort. 
 
5:1:7 Child behaviour checklist 
This parent-reported psychometric measure assesses emotional and 
behavioural problems in children aged 4-18 years. The first part concerns 
social skills, participation in organizations, contact with friends, participation 
and skills in sports and academic performance ratings. This section proved 
particularly taxing. Section one asks parents to name three types of sport 
their child likes to take activity in. In the majority of cases parents reported 
that their children had very few sports that the child liked to take part in, 
naming one or less in the majority of cases. This is an interesting finding. It 
may suggest that paediatric migraineurs take part in less physical activity 
than migraine free peers. Reflecting upon the potentially alternative 
mechanisms in the obesity and migraine relationship (chapter1.2.5) this is an 
important qualitative finding. This may be a preliminary finding that 
migraineurs have reduced exercise levels, placing them at increased risk of 
obesity. Alternatively, all children in Liverpool may do less exercise than 
other parts of the United Kingdom. Or potentially, as discussed in chapter 
1.2, it may simply be that sedentary activities are increasingly replacing 
active hobbies in the entire paediatric population.  
Section two asks parents to report three of their child‘s interests/hobbies, 
excluding radio, TV and computer. The majority of parents reported children 
had few hobbies other than computers or TV, and so few parents could name 
three hobbies.  Section three asks parents to name up to three organized 
clubs their child belongs to. Again, the majority could name a maximum of 
one club, possibly due to the lack of activities available for children in the 
geographical area. Alternatively, it may be that migraine causes general 
inertia and aversion to activity. Or, the recent advent of social networking on 
personal computers might be thwarting activity. There are a plethora of 
reasons for such findings, but, irrespective of the cause, it led to leaving the 
questionnaire incomplete. 
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A limitation of the study was the presence of the child when parents were 
completing the section pertaining to the academic performance of that child, 
because it is plausible that parents would over-report the academic ability of 
the child. Equally, a sub section asks parents to report concerns over their 
child; it is possible they would underreport such issues. 
The second part of the questionnaire deals with emotional and behavioural 
problems classified as internalized or externalized (full explanations of which 
are in the chapter 4:2:6). Parents answer on a 3-point Likert scale to indicate 
how representative the items are of the child‘s behaviour during the 
preceding six months. As above, it is possible the parents underreport poor 
behaviour such as ‗temper tantrums‘ or ‗cruelty, bullying or meanness to 
others‘, due to the presence of the child in the room. 
It is a fault of the study design that children are present whilst parents 
answer the tool, but it is very possible that this it reduces the validity of the 
answers.  In addition to this, the tool takes 20 minutes to complete, the same 
length it takes to complete all the others combined.  From this preliminary 
data it can be deduced that the CBCL was laborious to utilise because of the 
length of time it took to complete. It is however, widely used in both 
paediatric research and paediatric clinical practice. 
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Chapter 6: Discussion 
6:1 Discussion of results: 
In the course of this research formal assessment of various appetite 
behaviours, food cravings, food intake and psychological behaviours have 
been carried out in a paediatric migraine population. Unfortunately, due to a 
number of limitations of this study, discussed in detail in chapter 6.4, it is 
difficult and inappropriate, to draw firm quantitative conclusions from the 
study‘s findings.  
The sample size of these results must be highlighted, in order to put these 
results into perspective. The results in chapter 5 are preliminary; there is 
acute awareness that the study is at a nascent stage and that for more 
meaningful conclusions a greater sample size is needed. 
What can be gleaned from the early stages of this pilot study is that a 
successful comprehensive literature search was achieved. Furthermore, a 
great deal about the feasibility of the study design, and in particular the 
suitability of the relevant psychometric tools, has been learnt. This warrants 
further discussion.  
With regards to the study design, there are a couple of issues. Although the 
ethical approval delay was the main rate-limiting factor in recruitment of 
participants, once ethical approval was gained recruitment was slower than 
anticipated. This was due to the necessary inclusion criteria that participants 
were migraine medication naïve. This inclusion criteria is an advantage of 
the study. As mentioned in chapter 1.1.9, prophylactic migraine medications 
can alter weight and presumably appetite behaviour. Therefore drug naïve 
migaineurs were essential. Furthermore, by recruiting newly referred 
migraineurs the study is capturing participants at an early stage of their 
migraine trajectory. Cases of migraine are generally referred when the 
severity of migraine is at a point that it warrants specialist intervention.  
Therefore this inclusion criteria aimed to capture a population of migraineurs 
at the same point in their trajectory of a chronic disease. Comparing this to 
the methods employed in the previous studies reviewing the migraine and 
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obesity relationship (chapter 3), this is a novel, advantageous component of 
this study design. In potential further prospective study, this inclusion 
criteria will be crucial in trying to elucidate causation between migraine and 
obesity.  
It was surprisingly laborious to recruit control participants for the study. In 
the original design of the study, a control arm was not integral to the design, 
since the focus was on the association of appetite behaviour and migraine, 
and the analysis would focus on this. The study aimed to map appetite 
behaviour of migraine patients. There are normative data values that exist 
for the general population for the relevant measures, although not always of 
the exact same age group. Therefore a control arm of the study could be 
continued until completion, but is not essential to the study.  
With regard to the psychometric tools used in the design, there are a number 
of issues as highlighted in the qualitative results that need addressing.  
There were some issues with the pedMIDAS tool. Firstly, with regards to 
the clarity of its questions and that its design potentially lends to recall bias. 
Furthermore, the suitability of its questions to its proposed demographic was 
suboptimal. The tool has not been independently validated. Reflection upon 
whether the pedMIDAS accurately addresses migraine severity and, 
therefore, whether it is suitable for the purposes of this study, must be 
considered.  
Secondly, there were minor issues with DEBQ tool. There was lack of clarity 
in a couple of the questions. There was also an issue that participants gave 
polarised results on the Likert as a proxy for affirmative or negative 
responses. Although not utilised in the inception of the recruitment, the 
DEBQ-C overcomes this issues by being a three-point scale, reducing patient 
acquiescence in answering. Overall, however, the DEBQ was a very useable 
tool. Therefore with a couple of minor recommendations this tool is suitable 
for continued use in the study design. It is notable that the DEBQ has been 
widely used in previous studies to assess appetite behaviour. In previous 
work the DEBQ subscales have been utilised in neuro-imaging studies which 
associated certain appetite behaviours with neurotransmitter release(213). In 
potential further research the DEBQ may be able to be mapped with neuro-
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imaging of migraineurs.  
Similarly, the CEBQ was an easily utilised tool. Again, there was an issue 
with the clarity of a couple of the questions in the tool. The tool did, 
however, address the relevant appetite behaviours. Furthermore, the ‗reverse 
scoring‘ element of the tool is a particular strength, leaving it less vulnerable 
to participant acquiescence than the DEBQ. After addressing the minor 
problem of clarity of a couple of the questions in this tool, it will be suitable 
for continued use in the study design.  
The FIQ was utilised in a different fashion from that intended by its authors. 
Firstly, questions were asked of participants verbally. Previously the tool 
was administered for the child to record results on paper. Secondly, parents 
were in attendance when the participant was answering questions. 
Previously, the participant answered the tool in the absence of their 
parent/carer. Thirdly, the tool had previously been administered to a much 
larger number of children e.g. over 700 patients in one study(205).  Fourthly, 
the tool had previously been administered to children over 10 years old. This 
is important because it is possible that children at the younger end of the age 
spectrum would fail to fully understand the questions asked of them in the 
tool. Therefore reflection about the tools suitability in the study and, 
subsequent recommendations are merited.  
The FCI was an easily utilised and illuminated food cravings in the 
preliminary migraine population studied. It has been previously successfully 
used in different demographics, from normal weight subjects to obese 
subjects with mood disorders(126, 214). Therefore it is suitable for use in the 
continued study.  
The CBCL was very laborious to use, due to the length of time it took to 
complete (20minutes). Additionally, the tool was utilised in the presence of 
the child; in previous studies it is utilised in the absence of the child. These 
issues deserve reflection in the recommendations section for the continued 
study.  
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Chapter 6:2: Recommendations: 
The research performed by this author has failed to show any significant 
statistical findings. Current results cannot confirm whether or not migraine 
is associated with aberrant appetite behaviours at this preliminary stage. 
There were, however, qualitative findings about the rigor of the 
methodology of the study, in particular the applicability of certain 
psychometric tools. These issues must be dealt with to improve the 
continuation of this study. Furthermore, there are a number of different 
avenues that could be exploited to further research in this area. 
For firmer conclusions to be drawn about the relationship between migraine 
and appetite behaviours, it is imperative that this study is continued. With 
the study having achieved full ethical and site-specific approval, and 
producing preliminary results, the full pilot study of 90 patients (60 cases 
and 30 controls) should be conducted. From the results, a larger scale study 
should be conducted on a 900 participants.   
Chapter 6.2.1: Adaptations to study design 
Migraine severity measurement tool:  
The pedMIDAS tool had a number of limitations as highlighted in the 
discussion. To ensure that migraine severity is accurately recorded in the 
continuation of the study the following issues must be addressed. Discussion 
about the potential recall bias also needs to be addressed. Potential 
alternative methods of measuring migraine severity are migraine diaries and 
calendars. A number of migraine diaries have been designed(215), and 
applied in a number of settings, from scientific research to drug trials. They 
require the migraineur to record a number of details of each migraine attack 
e.g. length of attack, pain etc. The advantage such tools have are that they 
reduce recall bias, a key problem with the pedMIDAS. Ones study highlights 
that psychometric tools measuring severity of migraine overestimate its 
severity compared to migraine diaries(216).  Migraine diaries are, however, 
more labour intensive for the participant. Furthermore their success depends 
on the diligence of the participant in completing the diary or calendar. 
Moreover, if applied to this study, they would necessitate a further meeting 
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with the participant, entirely altering the recruitment process. Another 
alternative option would have been to replace the tool with an equivalent i.e. 
the HIT-6 questionnaire. A potential problem with replacing the pedMIDAS 
with another migraine severity tool, that has not been first utilised in 
preliminary studies, is that is may have an equal amount of limitations that 
will hinder the validity of the large- scale study. Therefore, due to the nature 
of the study, which is a pilot study with expedient recruitment design, a diary 
is not warranted for the study, even if it is the zenith of migraine severity 
prediction. Furthermore, it was be foolish to blindly replace one 
psychometric tool that measures migraine with another, particularly as the 
HIT-6 tool is a designed to measure adult migraine. Furthermore, the 
pedMIDAS, for all its limitations, is a tool that has been used widely in 
international studies. Therefore, overall, after addressing the issues of the 
pedMIDAS tool, it should remain the primary outcome measure for 
predicting migraine severity for the reasons highlighted above.  
Appetite behaviour measurement tool 
As highlighted in the discussion, both the CEBQ and DEBQ tools were 
useable and had good face validity in mapping appetite behaviours. Therefore 
they should continue to be used as the tools to assess appetite behaviour in 
this study. It would be beneficial to clarify with the authors of the DEBQ the 
issue of ambiguity over question 3 and question 9.   Similarly it would be 
beneficial to contact the authors of the CEBQ about the issue of ambiguity 
over question 28 (―Even if my child is full up s/he finds room to eat her/his 
favourite food?‖). Carers were unsure whether the food that had satiated the 
participant was also their favourite food or not, because this would alter the 
answer given.  It would be useful to discuss how to record answers when two 
parents give conflicting scores in the CEBQ, as occurred a couple of times in 
preliminary recruitment. In spite of these minor issues, the DEBQ and CEBQ 
should remain the appetite behaviour tools in the continued study.  The 
disparity between the preliminary scores obtained from the DEBQ and the 
CEBQ was surprising. Many of the questions focus on an overlapping 
concept e.g. external eating behaviours. This highlights the importance of 
having a self-reported tool and parent-reported tool because, although only 
very preliminary results, it is already shown there is a difference in 
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perception of appetite behaviour between the two. It is crucial that both tools 
are kept in the design for the entirety of the study, to highlight if these 
differences remain in a bigger population.  None of the average score results 
were statistically significant, therefore, robust conclusions on the disparity 
between the CEBQ and DEBQ cannot be drawn. For the full study, however, 
it will be important to keep both the DEBQ and CEBQ in the study design to 
see if, with a large sample size, the results become more consistent with one 
another. It would be useful, once the study is complete, to correlate 
individual items of each tool to assess if there is any relationship between 
their constructs. The authors of the CEBQ have supported this idea.  
An alternative way of measuring appetite behaviour would be to have utilised 
ingestive laboratory studies. The University of Liverpool has a group known 
as the Liverpool Obesity Research Network (LORN); who regularly study 
participants‘ appetites in a number of ingestive laboratory settings(217, 218). 
Theoretically, studying migraineurs trait appetite behaviours in this way 
would be a more direct measurement of appetite. Comparable appetite 
constructs assessed in appetite psychometric tools can be measured in these 
laboratories e.g. satiety responsiveness; by feeding subjects to supposed 
satiation and then offering a further highly palatable food to assess if they 
continue to eat. There are a plethora of different appetite constructs assessed 
in ingestive laboratories, beyond the remit of this thesis. This type of 
assessment of appetite behaviour is direct, being less prone to limitations 
(mentioned above) of a psychometric tool. This type of study would, 
however, be far more demanding on the participant and more costly. 
Therefore for the pilot study this was unfeasible. This methodolology of 
appetite assessment is worth due consideration for future study in this area.  
Reflecting on the qualitative results of the CBCL questionnaire, these results 
showed that this tool was a laborious one to use, taking twenty minutes to 
complete. Moreover, due to the study design, whereby participants were 
present whilst parents/carers answer questions about the participant‘s 
behaviour, the validity of scores are called into question. Consequently, 
parents/carers should be asked the CBCL questions without the participant 
present. The CBCL is a well-established tool in assessing paediatric 
psychological traits. Therefore although it is time consuming, no 
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parent/carer actually refused to answer the tool due to the length of time it 
took to complete. Furthermore, this tool has been used in a number of 
previous studies to assess the behaviour of migraineurs, consistently 
highlighting that migraine sufferers have higher internalisation scores(219, 
220). Therefore, because it has been so widely used in migraine patients, and 
yielded consistent results, although it is laborious to use, it should remain in 
the study but with the above recommendation.  
The preliminary FIQ scores suggested underreporting across all of the 
domains of the tool. As mentioned in the discussion, the tool was utilised in a 
different manner from that intended by its authors, which may be a reason 
for the underreporting; equally the sample size may be the cause of this. The 
tool has been used extensively before successfully, therefore it is 
recommended that the tool is included in the study with the following 
changes: Firstly, the participant completes the tool by hand (not verbally). 
Secondly, the participant is not in the presence of the parent when 
completing the tool.  Practically, when the parents/carers need to answer the 
CBCL the child could enter another room supported by clinic nurse and fill 
out the FIQ. This will make the recruitment phase more efficient. This is 
feasible because in the preliminary recruitment of the study the clinic nurses 
were available and supportive of aiding recruitment. A much larger sample 
size is necessary to glean meaningful results for the FIQ. It is unclear what 
samples size is needed because it is being used in a novel area. As such, it is 
recommended to continue to be used in this study until completion with the 
above recommendations.  
As highlighted in the discussion, the FCI was useable and accurately focused 
on food cravings. For continuation of the study, the tool should remain in the 
study design. Contact with the authors of the tool should be made to discuss 
the replacement of certain American foodstuffs with British equivalents, to 
ensure consistency is up kept when utilising the tool.  
Recruitment was slower than predicted, mainly due to the inclusion criteria 
that participants must be new patients who were migraine medication naïve. 
For the successful completion of the study it will be imperative to increase 
the potential recruitment population size. As previously designed, the most 
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feasible way of managing this is to recruit participants from the general 
paediatric clinic. Although this avenue was previously unfruitful due to 
another planned concurrent migraine study (which has still yet to 
commence), potentially this may be readdressed. Since the end of recruitment 
for this MPhil, a research nurse has been appointed for the alternative 
migraine study. Within their study design is the aim to recruit from the 
tertiary paediatric migraine clinics as well as general paediatric clinics. 
Therefore, pragmatically, it is feasible that strong collaboration between the 
primary investigator of this study and the research clinic nurse would result 
in a larger recruitment population. To catalyse this, a further meeting 
between the general paediatric consultants, neurology consultants, the 
research clinic nurse and the primary investigator is needed to readdress this 
issue. If this remains an unfruitful avenue, potential alternatives are possible. 
Recruitment from another paediatric hospital in the region is possible. Both 
St Helens and Knowsley Teaching Hospitals NHS Trust and Wirral 
University Teaching Hospital have paediatrics units that manage migraine. 
Therefore, with amendment to the both the study design and ethics 
application to make the study multi-centre, this would be very likely to 
improve recruitment rates. One logistical issue with this option is that there 
is not funding in the study for another study recruitment officer, therefore it 
may be unfeasible for the primary investigator to work between two sites. 
Considering, however, that recruitment was not occurring every day at the 
current site then it may be the most pragmatic option.  
The control arm of the study, whereby there are thirty non-migraine 
participants, was strongly suggested by the statistician when designing the 
study. This was not part of the preliminary study design. The recruitment of 
control participants was more arduous than migraine participants. Migraine 
is the most common referral to the paediatric headache clinic at Alder Hey 
Children‘s NHS Foundation Trust. More generally, migraine is more 
prevalent than other types of paediatric headache e.g. tension type 
headache(221). Therefore this is a key reason why it was hard to recruit 
control participants. Considering this, and that there are data norms for each 
of the psychometric tools, it is recommended to recruit only migraine 
participants into the pilot study for the continuation of the study.  
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6.2.2 Further potential research 
There is room for further research in this area. As mentioned in chapter 1:1, 
many migraine medications affect the weight of their users. Pizotifen, a very 
commonly used prophylactic migraine treatment, has been shown to cause 
weight gain (45, 50, 53). Conversely, Topiramate, another prophylactic 
migraine medication, has been shown to cause weight loss(36). Potential 
further research could be the design of a longitudinal study that assesses the 
weight, appetite behaviours, migraine severity, food cravings and food intake 
of migraine participants on these migraine medications. Theoretically, at 
baseline, i.e. when participants are prescribed the relevant prophylactic 
medication, participants could answer the psychometric tools from this study 
design.  Developments could then be followed up at 6 months and 1 year, 
reassessing the aforementioned parameters at each stage. Such a study would 
highlight whether particular appetite behaviours have a role in weight 
change. It would be useful to assess whether participants‘ migraine severity 
is associated with changes in weight. Based on this author‘s current 
hypothesis, it could be postulated that with Topiramate, which can causes 
weight loss, the participant‘s migraine severity and hypothetical aberrant 
appetite behaviours are reduced. Conversely, it could be postulated, that with 
the use of Pizotifen, which can cause weight gain, the patient‘s migraine 
severity and hypothetical aberrant appetite behaviours worsen. This is a 
novel concept that, hitherto, has not been studied.  Such a future study may 
have wider implications for the choice of pharmacological therapy for 
management of migraine. 
Another aspect of this further study, or even a separate study would be to 
assess the exercise levels of paediatric migraineurs. The type of 
measurements and their respective degrees of accuracy in measuring exercise 
vary. Self-report questionnaires to assess number of participant activities, 
and parental perception of their child‘s exercise levels have previously been 
designed and utilised(96, 222). Objective assessment of migraineur activity 
could be obtained by utilising accelerometers for participants to wear for a 
fixed period e.g. seven days (223). Alternatively, isotopes have been utilised 
to assess energy expenditure in subjects(224). Both of the latter methods 
would be more costly and require more specialist input than a self-report 
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questionnaire. They may, however, offer greater insight into the activity 
levels of migraineurs. Irrespective of the eventual methodology chosen to 
assess exercise, considering that potentially exercise could mediate the 
relationship between migraine and obesity (see chapter 1.2.5) and, is hitherto 
not been studied, this is a worthwhile aspect of study for the future.  
Potential further research in this field could be a population based study 
correlating primary headache with obesity and headache with diet. A very 
large cohort of children, 13,971 in total, have been monitored since in utero 
in a study called ―The Avon Longitudinal Study of Parents and Children 
(ALSPAC)(225)‖. This prospective longitudinal study of this cohort assesses 
all of life data (data from birth and annually hereafter), but is particularly 
interested in the anthropometry of these children over time.(226) 
Throughout the study, details of children‘s weight, BMI, waist 
circumference, and Dual–Energy X-Ray Absorpitometry (DXA) 
measurements of total and regional fat mass, are recorded at regular 
intervals(227). There is also detailed data on diet in this study, recorded at 3, 
7 and 12 years old, utilizing a food frequency questionnaire on the latter two 
occasions (227). The study has also measured primary headache frequency at 
regular intervals. Ultimately, it would be interesting to collaborate with the 
authors of this study and exploit such a rich volume of data, the largest 
longitudinal data on paediatric headache in the U.K.  If successful 
collaboration occurs, correlation of headache with weight and headache with 
diet on a population based scale can be conducted; a novel design that has not 
been conducted in the British paediatric population. Based on previous work 
the hypothesis would be that increased severity of migraine is associated 
with increased weight. More importantly, because data have been collected 
since the birth of participants and it is a longitudinal study, causation 
between the migraine and obesity relationship could potentially be 
elucidated.  
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6:3 Implications of the study: 
The implications of the quantitative results of this study are very limited due 
the limited sample size of the study thus far. There is not a strong enough 
body of results to suggest the need for a change in clinical practice. It is 
possible, however, to envisage that if further investigation found positive 
association between migraine and appetite, that there could be a number of 
implications for clinical practice. 
Children who are overweight in youth are at increased risk of being 
overweight in adulthood(69, 228). The consequences of being overweight are 
discussed in chapter 1.2. Theoretically, if it is identified in further study that 
migraineurs are at increased risk of increased adiposity, the implications are 
multiple; from simple implications such as increasing the frequency of a 
child‘s BMI measurement in migraine clinics, to ensuring all paediatric 
neurologists give greater attention to the weight and appetite of their 
migraine patients. 
There are a number of behavioural methods(134, 229) that could potentially 
be very useful at ameliorating the effects of aberrant appetite behaviours. As 
the current study has no robust conclusions from the association between 
appetite behaviour and migraine, these potential implications are merely 
postulations. 
More immediately, the body of work so far has implications for the 
experience of recruitment and utilising the psychometric tools in this 
preliminary work. Adopting the recommendations the study design should 
become more robust, and hence the full pilot study results gleaned should be 
reliable. Once the study is completed, it will be more appropriate to 
determine implications of the study.  
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Chapter 6:4 Limitations of the study or study design: 
6:4:1 Application for ethical and site-specific approval 
There are a few factors that limited the potential to draw rigorous 
conclusions. The largest rate-limiting factor of undertaking this study was 
the process of gaining ethical and site-specific approval for the study. The 
hypothesis and study design were only conceived subsequent to the inception 
of the MPhil. Accordingly, the first few months were spent immersed in 
literature reviews and protocol design (with multiple iterations). The 
primary investigator was informed to apply for site-specific approval prior to 
applying for local ethics research committee approval and the application for 
site-specific authorization was finalized in January 2009.  The process of site 
specific application involves applying to the R&D department with all 
relevant documentation, which is then referred to the primary reviewer and 
expert reviewer (from the relevant field of interest) who oversee the study. 
The reviewers then suggest changes to the study and further review the 
amended study design and, if of acceptable standard, the R&D committee 
reviews the application, comprised of ethicists, clinicians, statisticians and 
researchers, at the next available monthly meeting. There was significant 
delay by the R & D department in assigning the study a primary and expert 
reviewer. In mid February, after further liaison with the R&D department, it 
was decided that the study would not be reviewed in time for the next 
meeting, therefore delaying the review until late March. For unknown 
reasons the March meeting was subsequently cancelled by the R&D 
department. The primary investigator decided to discount the advice given 
by R&D not to simultaneously apply to the Local Ethics Research 
Committee, so that both applications would be completed in the same 
timeframe and the study could be commenced. Two reviewers were assigned 
to the study by the R&D department in very late March, therefore by the 
time the reviewers had given suggested changes the study could not enter in 
April R&D committee meeting. In the interim, this author attended the Local 
Ethics Committee review meeting and, achieved ethical approval subject to 
minor amendments (ref number: 09/H1017/51). The study was finally 
reviewed by the R&D department in early May and was given conditional 
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approval, subject to a few very minor adjustments. As a result of the 
aforementioned delays, the recruitment of the study did not start until the 
beginning of June. 
It is unclear whether this process of site-specific approval was abnormally 
prolonged, or whether it was shortsighted to undertake a project from a 
nascent stage in the one-year timeframe. Irrespectively, this process is a 
large limitation of the study. There are two potential solutions to this large 
limitation. Firstly, for robust conclusions to be drawn about the study‘s 
hypothesis, the study needs to be continued until completion, as originally 
envisaged. Secondly, for this study to be completed in this last year, 
application for ethical and site-specific approval should have been obtained 
prior to the commencement of the MPhil. These unexpected setbacks have 
taught the author a large amount about rigorous study design and research 
applications; a valuable, transferable skill. 
6:4:2 Limitations of the recruitment process 
As mentioned in the study design, a key part of the inclusion criteria was to 
recruit only newly referred migraine patients who were drug naïve.  The 
concept behind patients being new referrals was that these migraineurs 
should, in theory, have a relatively new diagnosis of migraine sufficiently 
severe for specialist referral, or have had a progression to a more severe 
migraine warranting specialist referral. Recruiting this type of migraine 
patient ensured that the study encompassed a group of migraine patients 
with the most severe migraine, i.e. more aberrant neurobiology. Previous 
work on migraine and obesity has shown that it is at the more severe end of 
the migraine severity spectrum that there is a relationship with obesity (44). 
Reflecting upon this, and the neurobiology review in chapter 2.2, recruiting 
this group of severe migraine sufferers would mean this population would be 
most likely to express aberrant appetite behaviour.   
The concept behind participants being drug naïve was that, many of the 
migraine treatments, namely Topiramate and Pizotifen, cause overt weight 
change (as highlighted in section 1.1) potentially through disruption of 
normal appetite behaviour (though this has currently not been studied). It 
was therefore important that any newly referred patient who had been 
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prescribed any such medication was excluded from the study. 
Unpublished internal figures suggest that there are ten new migraine 
referrals per month at Alder Hey. Less than 50% of potential participants 
were recruited into the author‘s study. To counter this problem, extensive 
efforts were made to build a relationship with general paediatricians at Alder 
Hey hospital, who deal with a smaller, but still substantial number of 
migraine referrals. After a number of preliminary meetings it became clear 
this avenue was obstructed by a concurrent large multi-centre randomized 
control trial into migraine (173).  
With the aforementioned issues surrounding ethical approval, combined with 
the issues in recruitment, due to necessarily rigid inclusion criteria and poor 
recruitment response rate, these factors greatly limited the potential of the 
study. 
6:4:3 The potential bias of a hospital clinic based study 
A second limitation of this study‘s design, from an epidemiological point of 
view, is that the study population is recruited from a tertiary clinic. Firstly, 
clinic based studies of co-morbidity are vulnerable to overestimating the 
condition due to a phenomenon known as Berkson bias(230). Any two 
conditions may occur at higher frequency at clinic due to consultation or 
referral, therefore, an indefensible criticism of the study design is that it 
could potentially overestimate aberrant patterns of appetite. 
Similarly, it is likely that many of the migraineurs who attend tertiary clinics 
are those at the most severe end of the migraine spectrum in terms of 
headache-associated disability. Those with the greatest impact on their life 
due to migraine are those most likely to seek specialist care, or be referred to 
a specialist. It could, therefore, be argued that, by focusing on a population of 
severe migraineurs, that this is not a true representation of the general 
population of migraine sufferers; findings of aberrant appetite behaviours in 
this severe migraine population might not, therefore, be representative of the 
general migraine population‘s appetite behaviours. 
Although both of these criticisms of a clinic-based population are fair, it is 
equally fair to suggest that a clinic-based population is suitable for a pilot 
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study of a novel hypothesis. For firm conclusions on the relationship between 
migraine and appetite to be made, a population-based study will be necessary. 
For a pilot based study, aiming for preliminary findings in appetite behaviour 
of migraineurs, a clinic-based population is more feasible, both fiscally and 
for recruitment purposes. 
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6:5 Conclusion: 
Drawing robust conclusions from this study is not possible. Ultimately, the 
sample size of the results prevents definitive insights into the relationship 
between migraine and appetite behaviour.  There are however, some 
interesting preliminary results about the study design and tools of the study. 
The recommendations chapter (section 6.2) highlights the necessary changes 
to improve the study in response to the qualitative findings, in order that 
robust quantitative findings can be elucidated when the study is continued to 
completion.  
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Appendix A: International Headache Society classification of headache(206): 
1.1 Migraine without aura 
Previously used terms: 
Common migraine, hemicrania simplex 
Description: 
Recurrent headache disorder manifesting in attacks lasting 4-72 hours. Typical 
characteristics of the headache are unilateral location, pulsating quality, moderate or 
severe intensity, aggravation by routine physical activity and association with nausea 
and/or photophobia and phonophobia. 
Diagnostic criteria: 
A. At least 5 attacks
1
 fulfilling criteria B-D 
B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
2;3;4
 
C. Headache has at least two of the following characteristics: 
1. unilateral location
5;6
 
2. pulsating quality
7
 
3. moderate or severe pain intensity 
4. aggravation by or causing avoidance of routine physical activity (eg, walking 
or climbing stairs) 
D. During headache at least one of the following: 
1. nausea and/or vomiting 
2. photophobia and phonophobia
8
 
E. Not attributed to another disorder
9
 
 
Notes: 
1. Differentiating between 1.1 Migraine without aura and 2.1 Infrequent 
episodic tension-type headache may be difficult. Therefore at least 5 attacks 
are required. Individuals who otherwise meet criteria for 1.1 Migraine without 
aura but have had fewer than 5 attacks should be coded 1.6.1 Probable 
migraine without aura. 
2. When the patient falls asleep during migraine and wakes up without it, 
duration of the attack is reckoned until the time of awakening. 
3. In children, attacks may last 1-72 hours (although the evidence for 
untreated durations of less than 2 hours in children requires corroboration by 
prospective diary studies). 
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4. When attacks occur on 15 days/month for >3 months, code as 1.1 
Migraine without aura and as 1.5.1 Chronic migraine. 
5. Migraine headache is commonly bilateral in young children; an adult 
pattern of unilateral pain usually emerges in late adolescence or early adult 
life. 
6. Migraine headache is usually frontotemporal. Occipital headache in 
children, whether unilateral or bilateral, is rare and calls for diagnostic 
caution; many cases are attributable to structural lesions. 
7. Pulsating means throbbing or varying with the heartbeat. 
8. In young children, photophobia and phonophobia may be inferred from 
their behaviour. 
9. History and physical and neurological examinations do not suggest any 
of the disorders listed in groups 5-12, or history and/or physical and/or 
neurological examinations do suggest such disorder but it is ruled out by 
appropriate investigations, or such disorder is present but attacks do not occur 
for the first time in close temporal relation to the disorder. 
Comments: 
1.1 Migraine without aura is the commonest subtype of migraine. It has a higher 
average attack frequency and is usually more disabling than 1.2 Migraine with aura. 
Migraine without aura often has a strict menstrual relationship. In contrast to the first 
edition of The International Classification of Headache Disorders, this edition gives 
criteria for A1.1.1 Pure menstrual migraine and A1.1.2 Menstrually-related 
migraine, but in the appendix because of uncertainty over whether they should be 
regarded as separate entities. 
Very frequent migraine attacks are now distinguished as 1.5.1 Chronic migraine 
provided that there is no medication overuse. Migraine without aura is the disease 
most prone to accelerate with frequent use of symptomatic medication, resulting in a 
new headache which is coded as 8.2 Medication-overuse headache. 
Regional cerebral blood flow shows no changes suggestive of cortical spreading 
depression during attacks of migraine without aura although blood flow changes in 
the brainstem may occur, as may cortical changes secondary to pain activation. This 
contrasts with the pathognomonic spreading oligaemia of migraine with aura. In all 
likelihood spreading depression is therefore not involved in migraine without aura. 
On the other hand the messenger molecules nitric oxide (NO) and calcitonin-gene-
related peptide (CGRP) are clearly involved. While the disease was previously 
regarded as primarily vascular, the importance of sensitisation of perivascular nerve 
terminals, and the possibility that attacks may originate in the central nervous system, 
have gained increasing attention over the last decades. At the same time the circuitry 
of migraine pain and several aspects of neurotransmission in this system have been 
recognised. A significant contribution has been made by the advent of the triptans, 
5HT1B/D receptor agonists. These drugs have remarkable efficacy in acute attacks and, 
in view of their high receptor-specificity, their mechanism of action provides new 
insight into migraine mechanisms. It is now clear that migraine without aura is a 
neurobiological disorder and clinical as well as basic neuroscience currently advances 
our knowledge of migraine mechanisms at an increasing speed. 
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1.2 Migraine with aura 
Previously used terms: 
Classic or classical migraine, ophthalmic, hemiparaesthetic, hemiplegic or aphasic 
migraine, migraine accompagnée, complicated migraine 
Coded elsewhere: 
13.17 Ophthalmoplegic “migraine”. 
Description: 
Recurrent disorder manifesting in attacks of reversible focal neurological symptoms 
that usually develop gradually over 5-20 minutes and last for less than 60 minutes. 
Headache with the features of migraine without aura usually follows the aura 
symptoms. Less commonly, headache lacks migrainous features or is completely 
absent. 
Diagnostic criteria: 
A. At least 2 attacks fulfilling criterion B 
B. Migraine aura fulfilling criteria B and C for one of the subforms 1.2.1-1.2.6 
C. Not attributed to another disorder
1
 
 
Note: 
1. History and physical and neurological examinations do not suggest any of the 
disorders listed in groups 5-12, or history and/or physical and/or neurological 
examinations do suggest such disorder but it is ruled out by appropriate 
investigations, or such disorder is present but attacks do not occur for the first time in 
close temporal relation to the disorder. 
Comments: 
The aura is the complex of neurological symptoms that occurs just before or at the 
onset of migraine headache. Most patients with migraine have exclusively attacks 
without aura. Many patients who have frequent attacks with aura also have attacks 
without aura (code as 1.2 Migraine with aura and 1.1 Migraine without aura). 
Premonitory symptoms occur hours to a day or two before a migraine attack (with or 
without aura). They include various combinations of fatigue, difficulty in 
concentrating, neck stiffness, sensitivity to light or sound, nausea, blurred vision, 
yawning and pallor. The terms prodrome and warning symptoms are best avoided 
because they are often mistakenly used to include aura. 
The majority of migraine auras are associated with headache fulfilling criteria for 1.1 
Migraine without aura. For this reason the entity 1.2.1 Typical aura with migraine 
headache has been singled out below. Migraine aura is sometimes associated with a 
headache that does not fulfil criteria for migraine without aura and, in other cases, 
migraine aura may occur without headache. These two subforms are also now 
distinguished. 
Aura with similar features has also been described in association with other well-
defined headache types, including cluster headache; the relationships between aura 
and headache are not fully understood. 
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Before or simultaneously with the onset of aura symptoms, regional cerebral blood 
flow is decreased in cortex corresponding to the clinically affected area and often 
including an even wider area. Blood flow reduction usually starts posteriorly and 
spreads anteriorly and is usually above the ischaemic threshold. After one to several 
hours, gradual transition into hyperaemia occurs in the same region. Cortical 
spreading depression of Leão has been implicated. 
Systematic studies have demonstrated that many patients with visual auras 
occasionally have symptoms in the extremities. Conversely patients with symptoms 
in the extremities virtually always also suffer visual aura symptoms. A distinction 
between migraine with visual aura and hemiparaesthetic migraine is probably 
artificial and therefore is not recognised in this classification. Patients with motor 
weakness are classified separately because of the dominantly inherited form, 1.2.4 
Familial hemiplegic migraine, and because of clinical differences. The genetic 
relationship between migraine with aura and familial hemiplegic migraine has not 
been established. 
The previously-defined syndromes migraine with prolonged aura and migraine with 
acute-onset aura have been abandoned. The great majority of patients with such 
attacks have other attacks that fulfil criteria for one of the subforms of 1.2 Migraine 
with aura and should be coded to that diagnosis. The rest should be coded to 1.6.2 
Probable migraine with aura, specifying the atypical feature (prolonged aura or 
acute-onset aura) in parenthesis. 
1.2.1 Typical aura with migraine headache 
Description: 
Typical aura consisting of visual and/or sensory and/or speech symptoms. Gradual 
development, duration no longer than one hour, a mix of positive and negative 
features and complete reversibility characterise the aura which is associated with a 
headache fulfilling criteria for 1.1 Migraine without aura. 
Diagnostic criteria: 
A. At least 2 attacks fulfilling criteria B–D 
B. Aura consisting of at least one of the following, but no motor weakness: 
1. fully reversible visual symptoms including positive features (eg, 
flickering lights, spots or lines) and/or negative features (ie, loss of vision) 
2. fully reversible sensory symptoms including positive features (ie, 
pins and needles) and/or negative features (ie, numbness) 
3. fully reversible dysphasic speech disturbance 
C. At least two of the following: 
1. homonymous visual symptoms
1
 and/or unilateral sensory symptoms 
2.  at least one aura symptom develops gradually over 5 minutes and/or different 
aura symptoms occur in succession over 5 minutes 
3. each symptom lasts 5 and 60 minutes 
D. Headache fulfilling criteria B-D for 1.1 Migraine without aura begins during 
the aura or follows aura within 60 minutes 
E. Not attributed to another disorder
2
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Notes: 
1. Additional loss or blurring of central vision may occur. 
2. History and physical and neurological examinations do not suggest any of the 
disorders listed in groups 5-12, or history and/or physical and/or neurological 
examinations do suggest such disorder but it is ruled out by appropriate 
investigations, or such disorder is present but attacks do not occur for the first time in 
close temporal relation to the disorder. 
Comments: 
This is the most common migraine syndrome associated with aura. The diagnosis is 
usually evident after a careful history alone though there are rare secondary mimics 
including carotid dissection, arteriovenous malformation and seizure. 
Visual aura is the most common type of aura, often presenting as a fortification 
spectrum, ie, a zigzag figure near the point of fixation that may gradually spread right 
or left and assume a laterally convex shape with an angulated scintillating edge 
leaving variable degrees of absolute or relative scotoma in its wake. In other cases, 
scotoma without positive phenomena may occur; this is often perceived as being of 
acute onset but, on scrutiny, usually enlarges gradually. Next in frequency are 
sensory disturbances in the form of pins and needles moving slowly from the point of 
origin and affecting a greater or smaller part of one side of the body and face. 
Numbness may occur in its wake, but numbness may also be the only symptom. Less 
frequent are speech disturbances, usually dysphasic but often hard to categorise. If 
the aura includes motor weakness, code as 1.2.4 Familial hemiplegic migraine or 
1.2.5 Sporadic hemiplegic migraine. 
Symptoms usually follow one another in succession beginning with visual, then 
sensory symptoms and dysphasia, but the reverse and other orders have been noted. 
Patients often find it hard to describe their symptoms in which case they should be 
instructed in how to time and record them. After such prospective observation the 
clinical picture often becomes clearer. Common mistakes are incorrect reports of 
lateralisation of headache, of sudden onset when it is gradual and of monocular visual 
disturbances when they are homonymous, as well as incorrect duration of aura and 
mistaking sensory loss for weakness. After an initial consultation, use of an aura 
diary may clarify the diagnosis. 
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Appendix B: Definition and background of chronic migraine(206): 
Chronic migraine 
Description: 
Migraine headache occurring on 15 or more days per month for more than 3 
months in the absence of medication overuse. 
Diagnostic criteria: 
A. Headache fulfilling criteria C and D for 1.1 Migraine without aura on 15 
days/month for >3 months 
B. Not attributed to another disorder1;2 
 
Note: 
1. History and physical and neurological examinations do not suggest any of the 
disorders listed in groups 5-12, or history and/or physical and/or neurological 
examinations do suggest such disorder but it is ruled out by appropriate 
investigations, or such disorder is present but headache does not occur for the first 
time in close temporal relation to the disorder. 
2. When medication overuse is present and fulfils criterion B for any of the subforms of 
8.2 Medication-overuse headache, it is uncertain whether this criterion B is fulfilled 
until 2 months after medication has been withdrawn without improvement (see 
Comments). 
Comments: 
Most cases of chronic migraine start as 1.1 Migraine without aura. Therefore, 
chronicity may be regarded as a complication of episodic migraine. 
As chronicity develops, headache tends to lose its attack-wise (episodic) 
presentation although it has not been clearly demonstrated that this is always so. 
When medication overuse is present (ie, fulfilling criterion B for any of the subforms 
of 8.2 Medication-overuse headache), this is the most likely cause of chronic 
symptoms. Therefore, the default rule is to code such patients according to the 
antecedent migraine subtype (usually 1.1 Migraine without aura) plus 1.6.5 
Probable chronic migraine plus 8.2.8 Probable medication-overuse headache. When 
these criteria are still fulfilled 2 months after medication overuse has ceased, 1.5.1 
Chronic migraine plus the antecedent migraine subtype should be diagnosed, and 
8.2.8 Probable medication-overuse headache discarded. If at any time sooner they 
are no longer fulfilled, because improvement has occurred, code for 8.2 Medication-
overuse headache plus the antecedent migraine subtype and discard 1.6.5 Probable 
chronic migraine. 
These criteria require further study. 
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Appendix C: STROBE Statement—Checklist of items that should be included 
in reports of case-control studies 
 Item 
No 
Recommendation 
Title and 
abstract  
1  (a) Indicate the study‘s design with a commonly used term 
in the title or the abstract  
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found 
Introduction 
Background/r
ationale 
2  Explain the scientific background and rationale for the 
investigation being reported 
Introduction 
Objectives 
3  State specific objectives, including any pre specified 
hypotheses  
Methods Study 
design 
4  Present key elements of study design early in the paper 
Methods 
Setting 
5  Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data 
collection 
Methods 
Participants 
6  (a) Give the eligibility criteria, and the sources and methods 
of case ascertainment  
and control selection. Give the rationale for the choice of 
cases and controls  
(b) For matched studies, give matching criteria and the 
number of controls per case 
Methods 
Variables 
7  Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect  
modifiers. Give diagnostic criteria, if applicable  
 
Methods Data 
sources/ 
measurement 
8*  For each variable of interest, give sources of data and details 
of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than 
one group 
 
Methods Bias 9  Describe any efforts to address potential sources of bias 
Methods Study 
size 
10  Explain how the study size was arrived at  
 
Methods 
Quantitative 
variables 
11  Explain how quantitative variables were handled in the 
analyses. If applicable,  
describe which groupings were chosen and why  
 
Methods 
Statistical 
methods 
12  (a) Describe all statistical methods, including those used to 
control for confounding  
(b) Describe any methods used to examine subgroups and 
interactions  
(c) Explain how missing data were addressed  
(d) If applicable, explain how matching of cases and controls 
was addressed  
(e) Describe any sensitivity analyses 
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Results 
Participants 
 
13
*  
 
(a) Report numbers of individuals at each stage of study—eg 
numbers potentially  
eligible, examined for eligibility, confirmed eligible, included 
in the study,  
completing follow-up, and analysed  
(b) Give reasons for non-participation at each stage  
(c) Consider use of a flow diagram  
 
Results 
Descriptive 
data 
14
*  
(a) Give characteristics of study participants (eg 
demographic, clinical, social) and information on exposures 
and potential confounders  
(b) Indicate number of participants with missing data for 
each variable of interest  
 
Results Outcome 
data 
15
*  
Report numbers of outcome events or summary measures  
 
Results Main 
results  
16  (a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and  
their precision (eg, 95% confidence interval). Make clear 
which confounders were  
adjusted for and why they were included  
(b) Report category boundaries when continuous variables 
were categorized  
(c) If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period 
Results Other 
analyses 
17  Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
Discussion Key 
results 
18 Summarise key results with reference to study objectives 
Discussion 
Limitations 
19 Discuss limitations of the study, taking into account sources 
of potential bias or imprecision.  
Discuss both direction and magnitude of any potential bias  
 
Discussion 
Interpretation 
20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity  
of analyses, results from similar studies, and other relevant 
evidence 
Discussion 
Generalisability 
21 Discuss the generalisability (external validity) of the study 
results  
 
Other issues 
Funding 
22 Give the source of funding and the role of the funders for 
the present study and, if applicable,  
for the original study on which the present article is based 
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 Item 
No 
Recommendation 
Title and 
abstract  
1  (a) Indicate the study‘s design with a commonly used term in 
the title or the abstract  
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found 
Introduction 
Background/
rationale 
2  Explain the scientific background and rationale for the 
investigation being reported 
Introduction 
Objectives 
3  State specific objectives, including any pre specified 
hypotheses  
Methods 
Study design 
4  Present key elements of study design early in the paper 
Methods 
Setting 
5  Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data 
collection 
Methods 
Participants 
6  (a) Give the eligibility criteria, and the sources and methods 
of selection of participants  
 
 
Methods 
Variables 
7  Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable  
 
Methods Data 
sources/ 
measurement 
8*  For each variable of interest, give sources of data and details 
of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than 
one group 
 
Methods Bias 9  Describe any efforts to address potential sources of bias 
Methods 
Study size 
10  Explain how the study size was arrived at  
 
Methods 
Quantitative 
variables 
11  Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were chosen 
and why  
 
Methods 
Statistical 
methods 
12  (a) Describe all statistical methods, including those used to 
control for confounding  
(b) Describe any methods used to examine subgroups and 
interactions  
(c) Explain how missing data were addressed  
(d) If applicable, explain how matching of cases and controls 
was addressed  
(e) Describe any sensitivity analyses 
Appendix D: STROBE Statement—Checklist of items that should be 
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Results 
Participants 
 
13
*  
 
(a) Report numbers of individuals at each stage of study—eg 
numbers potentially  
eligible, examined for eligibility, confirmed eligible, included 
in the study,  
completing follow-up, and analysed  
(b) Give reasons for non-participation at each stage  
(c) Consider use of a flow diagram  
 
Results 
Descriptive 
data 
14
*  
(a) Give characteristics of study participants (eg 
demographic, clinical, social) and information on exposures 
and potential confounders  
(b) Indicate number of participants with missing data for 
each variable of interest  
 
Results Outcome 
data 
15
*  
Report numbers of outcome events or summary measures  
 
Results Main 
results  
16  (a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and  
their precision (eg, 95% confidence interval). Make clear 
which confounders were  
adjusted for and why they were included  
(b) Report category boundaries when continuous variables 
were categorized  
(c) If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period 
Results Other 
analyses 
17  Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses 
Discussion Key 
results 
18 Summarise key results with reference to study objectives 
Discussion 
Limitations 
19 Discuss limitations of the study, taking into account sources 
of potential bias or imprecision.  
Discuss both direction and magnitude of any potential bias  
 
Discussion 
Interpretation 
20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity  
of analyses, results from similar studies, and other relevant 
evidence 
Discussion 
Generalisability 
21 Discuss the generalisability (external validity) of the study 
results  
 
Other issues 
Funding 
22 Give the source of funding and the role of the funders for 
the present study and, if applicable,  
for the original study on which the present article is based 
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Appendix F: Letter to the editor: 
This is the pre-peer reviewed version of the following article [Ray ST, 
Kumar R. Migraine and obesity: cause or effect? Headache.  Feb;50(2):326-
8](231), which has been published in final form at 
[http://onlinelibrary.wiley.com/doi/10.1111/j.1526-
4610.2009.01539.x/abstract]. 
The letter below was written in response to the study by Hershey et al(107). 
It was accepted by the International Journal Headache – the Journal of head 
and face pain.  
Title: Migraine and obesity: cause or effect? 
Authors: Stephen TJ Ray, Ram Kumar(MSc) (Ray S, Kumar R). 
Affiliations: Alder Hey Children‘s NHS foundation trust, Liverpool, 
England. 
Conflict of interest: No Conflict. 
Key words: Migraine, Obesity, BMI, appetite, eating behavior, adiposity. 
Letter to the editor: 
Abbreviations: BMI – Body mass index, pedMIDAS – pediatric migraine 
disability assessment,FTO - The fat mass and obesity associated CSF - 
cerebrospinal fluid. 
Migraine and obesity: cause or effect? 
We read with interest the paper by Hershey et al (i) showing that obesity was 
significantly correlated with headache frequency and disability in children as 
has been observed in adult population studies. We wish to highlight certain 
aspects of their method for further consideration. The study was a large, 
multi-centre, retrospective case – only series. Previous studies in this area 
have used categorical variables when measuring weight and migraine 
severity. This study used the PedMIDAS scale to measure headache severity, 
and measured adiposity with BMI centiles. This methodology is an advance 
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in the area since by utilising effectively continuous measures there is a higher 
power to detect an association. Raw BMI, as used in the study of Hershey et 
al, has been considered a poor measure of adiposity in the normal weight 
range in children because it does not distinguish well between fat and lean 
mass (ii). By contrast, the use of BMI Z scores have been described as optimal 
for assessing adiposity on a single occasion(iii). 
 
The authors detected a statistically significant association between BMI 
percentile and measures of headache severity. The association was modest (r 
= 0.10 and 0.08 for headache frequency and pedMIDAS respectively). One 
reason for this could be the incorporation of all primary headache types into 
the study. Previous associations between headache and obesity have been 
detected specifically within the category of migraine rather than tension-type 
headache(iv). It has been shown that obesity is a risk factor chronic migraine 
rather than chronic tension-type headache(v), and that high BMI increases 
migraine frequency(vi).  It would thus be interesting to perform a sub 
analysis in the group of patients having migraine with and without aura. 
Another reason for the low correlation between BMI and the measures of 
headache severity could be that there may be a non-linear association. 
 
Pinhas-Hamiel et al(vii) reported findings in line with the current study of 
Hershey et al. The study found that overweight females had a four times 
greater risk of headache compared to normal weight females (OR=3.93). The 
methodology of this study was a case control of 273 children. 
 
The authors note that the overall obesity prevalence in the cases reflected the 
latest general U.S paediatric obesity rates. The authors suggest that this may 
be due to some overweight children developing headaches that require 
treatment later in life; accounting for the increased representation of 
migraine among obese individuals in the adult population. This ties in with 
the hypothesis by Bigal and Lipton, that obesity is a risk factor for migraine 
chronification(viii). 
 
Alternatively, we hypothesize that migraine in children may increase 
adiposity, via eating behaviours. This is a biologically plausible hypothesis. 
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Firstly, because of the overlapping neurobiological mediators in migraine, 
appetite and obesity. For example, Calcitonin Gene Related Peptide (CGRP), 
is raised in the plasma of obese adults; it is also raised in the external jugular 
venous blood of animal models of obesity and also migraine patients. (ix,x,xi).  
In the rat model of obesity, administering exogenous CGRP increases intake 
of fat, and CGRP is elevated prior to the onset of obesity in animal models. 
CGRP and its receptors are now a major focus for pharmacological treatment 
of migraine (xii,xiii). Serotonin is another neurotransmitter pertinent to 
obesity, migraine and appetite. In appetite, serotonin is key to the process of 
feeding control including satiation, and signaling the satiety state.  Serotonin 
agonist drugs given to humans markedly reduce their appetite (xiv,xv), leading 
to weight loss (xvi). Migraine, on the other hand, has been characterised as a 
condition of relative brain serotonin deficiency. Thus one could hypothesize 
that in migraineurs there is a tendency for increased appetite (xvii). There is 
increasing interest in the role of orexins, in particular orexin A, in appetite 
control. Orexins are also involved in migraine. Orexin A levels were elevated 
in the cerebrospinal fluid (CSF) of migraine patients (xviii). It has been argued 
this is a compensatory response to chronic pain, for it has been suggested 
orexin A has antinociceptive properties (xix).   Orexins are incontrovertibly 
involved in the regulation of appetite behaviour (xx). Administration of orexin 
A to rats increases asuppetite and delays satiety(xxi), and orexin -1-receptor 
antagonists reduce appetite substantially in rats(xxii).  This overlap shows a 
crucial neurobiological link between eating behaviour and migraine, and 
underlines the importance of studying appetite and resulting eating 
behaviours, rather than just established obesity in this paradigm. 
Furthermore, there is interest in appetite behaviours as a mechanism for the 
development of obesity in children. Recent evidence suggests that 
neurobiological mediators of interindividual susceptibility to obesity can act 
via eating behaviour (xxiii,xxiv,xxv,xxvi). Willer et al reported that the common 
genes involved in human obesity are expressed in the central nervous 
system, implying the importance of studying behaviours to understand the 
control of weight (xxvi). The fat mass and obesity associated (FTO) gene, 
expressed in the hypothalamus, has received much recent interest since a 
common single nucleotide polymorphism was associated with obesity and 
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increased adiposity in children. Wardle et al have demonstrated the effect of 
the FTO genotype on increased adiposity being mediated through patterns 
of eating behaviour(xxiii). Another recent study in children from an ingestive 
laboratory demonstrated that the FTO polymorphism alters food choice 
towards energy-dense foods, independent of the child‘s current weight 
category (xxvii). Thus poor eating behaviours could increase adiposity, i.e. 
children who are currently within the ―normal‖ weight range, but at risk of 
proceeding to overweight and obese categories (xxviii). Findings that a 
neurobiological factor(the FTO gene) cause increased adiposity via its effects 
on appetite and eating behaviour, highlight that it is plausible that other 
neurobiological causes, such as migraine, could act similarly to have the same 
effect on adiposity. 
We feel it will be necessary to study the effects of migraine on eating 
behaviour. If a relationship exists between migraine and increased appetite, it 
may be possible to modify treatment before the establishment of obesity. 
Interventions to modify appetitive traits or ameliorate their impact on 
weight can be designed (xxix). Studying this in the paediatric population will 
further our understanding of the relationship between migraine and 
adiposity. Since both migraine and obesity evolve during the course of 
childhood, a study in the childhood population may be able to establish if 
migraine precedes the onset of obesity or vice versa, thus determining the 
causality of this relationship. We feel a prospective study confined to 
migraine patients will enhance results of the study by Hershey et al. 
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Appendix G: Patient information sheet: 
 
 
 
 
A study on the link between migraine, appetite behaviours and obesity. 
We would like to invite you and your child to participate in our research 
study. Before you decide to participate, we shall explain below why we are 
doing this study, and what it will involve for you and your child. 
Please take time to read the following information and discuss it with others 
if you wish. You can ask us for further information (see contact details at the 
end of this sheet). 
Why are we doing this study? 
Migraine can be a very disabling disease, and it is very common in children. 
There has recently been research in adults to suggest there is a link between 
severe migraine and obesity, which can cause worse headaches. Obesity is 
becoming very common in children, with 25% of children classified as obese. 
We therefore think it is important to investigate if severe migraine can cause 
poor eating in children leading to obesity. We aim to see if particular 
appetite behaviours can be seen in migraine patients, so that they can be 
addressed, and doctors can devise ways in which to change them to prevent 
the onset of obesity and worsening the patients‘ migriane. 
Why have you and your child been chosen? 
Based on the records at Royal Liverpool Children‘s Hospital, your child was 
noted to either have suspected migraine or have been diagnosed with 
migraine. You may remember meeting the leader of this study (Dr Ram 
Kumar) at a previous clinic appointment for your child‘s headache. We would 
like some information on how your child is doing from a health and 
education point-of-view. 
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Do I have to take part? 
It is up to you whether you take part in this research study. If you do decide 
to take part you will be given this information sheet to keep and be asked to 
sign a consent form. If you decide to take part you are still free to withdraw 
at any time and without giving a reason.  A decision to withdraw at any time, 
or a decision not to take part, will not affect any future medical care. 
What do my child and I have to do if we take part? 
We would like to invite you to attend the neurology department for a clinic 
appointment with the researchers. Whilst your child is attending for their 
appointment with the consultant, either prior to or after the appointment, the 
researcher will take you into a separate room, were firstly he will explain 
what the research is about and why we would like your child to be involved. 
Then we will explain the types of questions we are going to ask you and your 
child. Then we will ask you if you have any questions. Then we would ask 
whether you would like to take part. If you agree to do so, we will ask you, 
and your child to sign a consent form. Then we will ask you and your child 
all the questions from the questionnaires. This will take no more than one 
hour to complete. This is all we need you to do, once the study is finished, if 
you should wish, we will send you results of the study. 
What are the possible benefits of taking part? 
You and your child will be contributing to improving the care and health of 
other children in the future who are also diagnosed with migraine. 
What are the possible disadvantages and risks of taking part? 
We do not foresee any disadvantage to you or your child if you decide to take 
part in the study. There are no risks involved to you or your child, and no 
pain or discomfort will be caused. If you or your child become upset by any of 
the issues that arise from the questionnaires the consultant will happily give 
you counselling about them. Furthermore, if you have any concerns about 
the way in which you were approached or treated throughout the course of 
the research you can contact the hospital research department to voice your 
concerns (Details below). 
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Will my taking part in this study be kept confidential? 
We will keep all records from your child‘s questionnaire confidential. Only 
the named members (at the end of this sheet) of the research study team will 
have access to the records. 
What will happen to the results of the research study? 
We will analyse the results from all the participants in this study at the end 
of the study period. We will publish a report on our conclusions in a well-
reviewed medical journal. In addition, we will send you a copy of the report if 
you would like one. 
Who is organising and funding the research? 
This research study has been organised by the paediatric neurology 
department, Royal Liverpool Children‘s NHS Foundation Trust. There is no 
external funding for this study; the primary researcher has been funded to 
conduct the study by the Neurodisability trust. 
Who has reviewed the study? 
The Cheshire Research Ethics Committee has reviewed this study. 
Contact for further Information 
Please contact the research study members if you need any further 
information at any stage: 
 
Dr Ram Kumar 
Consultant Paediatric 
Neurology, 
Department of 
Paediatric 
Neurology, 
Royal Liverpool 
Children‘s Hospital, 
Eaton Road 
01512525164 
Stephen Ray 
Mphil Researcher 
Department of 
Paediatric 
Neurology, 
Royal Liverpool 
Children‘s Hospital, 
Eaton Road 
07709453694 
Dot Lambert 
Research and Development 
Manager 
Alder Hey Children's NHS 
Foundation Trust 
Direct tel: 0151 252 5673 
Internal ext: 3785 
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